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SUMMARY 
Gastrointestinal stromal tumours (GIST) are the most frequent mesenchymal neoplasms of the 
digestive system. The annual incidence of clinically relevant GIST is around 13 cases per 
million inhabitants, whereas small incidental forms (<1 cm in size), referred to as micro-GIST, 
are found in at least 30% of the elderly population. Interstitial Cells of Cajal (ICC), innervated 
cells which regulate the peristalsis of the bowel, are thought to be the GIST cell of origin, as 
they are both dependent on KIT tyrosine kinase receptor and share similar morphology and 
immunophenotype. Approximately 85% of GIST harbour gain-of-function mutations in KIT or 
PDGFRA genes, which represent initiating event in GIST development, triggering constitutive 
stimulation of the RAS/RAF/MAPK, PI3K/AKT/mTOR and JAK/STAT signalling cascades. 
These pathways are crucial for GIST cell proliferation, survival and migration. Nevertheless, 
although KIT/PDGFRA oncogenic mutations are necessary they are not sufficient for GIST 
malignant transformation. As a matter of fact, micro-GIST carry the same type of 
KIT/PDGFRA mutations, but they rarely progress into clinically significant GIST. This 
indicates that GIST oncogenic evolution is possibly supported by further genetic and epigenetic 
changes, and might be sustained by additional environmental stimuli. The biological 
mechanisms and the different factors involved in this multi-step malignant transformation are 
still largely unknown. Bearing in mind that first and second line treatment of aggressive GIST 
with tyrosine kinase inhibitors, such as imatinib or sunitinib, are rarely completely successful, 
a better understanding of GIST pathogenesis becomes necessary for the discovery of new target 
molecules, and the development of more effective treatments. 
In this thesis we have performed a comprehensive cytogenetic, molecular and functional 
characterization of GIST. In particular, we investigated the relevance of two selected genes, 
CCK2R and PTEN, and their contribution to GIST development and progression.  
CCK2R belongs to the superfamily of G protein-coupled receptors. It is expressed in the 
gastrointestinal tract, where it mediates the action of gastrin; it regulates gastric acid secretion 
as well as growth and differentiation of the gastric epithelium. After gastrin stimulation, 
CCK2R is able to activate important downstream signalling, e.g. PLC and PKC, RAS/MAPK 
and PI3K/AKT pathways, which promote cell survival, proliferation and invasion. 
Interestingly, activated CCK2R displays growth-promoting effects on pre-neoplastic 
gastrointestinal cells. Expression of CCK2R has been demonstrated in different type of cancers, 
while it was not found in the corresponding normal tissues. These observations suggest a 
potential role of CCK2R in tumour pathogenesis.  
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In this thesis, we have shown that CCK2R is commonly expressed in GIST of gastric origin. 
Moreover, we observed higher level of CCK2R in GIST characterized by low malignant 
potential in comparison with high-risk/malignant ones, irrespective of the tumour genotype. 
Notably, we have found expression of CCK2R also in cases of incidental ICC hyperplasia and 
gastric micro-GIST. In addition, by in vivo studies using human GIST xenografts, we have 
demonstrated that gastrin-dependent stimulation of CCK2R leads to increased cell proliferation 
and tumour volume. In fact, we observed hyper-activation of PKC-θ and KIT kinases, and 
subsequently over-activation of major downstream KIT signalling pathways (AKT and 
MAPK). These findings suggest a promoting role of gastrin and CCK2R in early stages of 
GIST evolution, particularly in tumours that arise in the gastric microenvironment.  
On the other hand, in this thesis we have found partial or total loss of PTEN expression in 
advanced malignant GIST, especially in tumour that showed resistance to imatinib therapy. 
This is in line with the common inactivation of crucial tumour suppressor genes in the late 
stages of GIST evolution. Furthermore, we have demonstrated that PTEN deficiency was 
primarily due to monoallelic loss of the PTEN gene. PTEN is a phosphatase that negatively 
regulates the PI3K/AKT signalling cascade. After in vitro silencing of PTEN in GIST cells, we 
have observed up-regulation of both the PI3K/AKT and the MAPK pathways, which are 
connected to each other by a complex network of cross-talks and feedback loops. Interestingly, 
we have found residual survival signalling after imatinib treatment and paradoxal over-
activation of MAPK after dual PI3K/mTOR inhibition with NVPBEZ235. Combined treatment 
successfully counteracted the effects of PTEN silencing on AKT and MAPK activation in 
imatinib-sensitive GIST cell lines, whereas substantial MAPK hyper-phosphorylation was still 
observed in imatinib-resistant cells. In this cell context concomitant inhibition of the 
PI3K/AKT and RAS/MAPK pathways should be tested. Our results highlight the importance 
of PTEN deficiency in GIST progression. Moreover, PTEN represents an important biomarker 
to properly select GIST patients for appropriate therapies. 
In conclusion, CCK2R expression and PTEN inactivation promote GIST progression at 
different stages, providing selective advantages to the tumour cells. Accumulation of 
aberrations during GIST malignant transformation leads to tumour heterogeneity, which 
influences the responses to treatment. A greater knowledge of crucial genes involved in GIST 
evolution will lead to an earlier diagnosis, better prognosis and more effective therapies. 
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SAMENVATTING 
Gastrointestinale stromale tumoren (GIST) zijn de meest voorkomende mesenchymale 
neoplasmen van het spijsverteringsstelsel. De jaarlijkse incidentie van klinisch relevante GIST 
is ongeveer 13 gevallen per miljoen inwoners. Micro-GIST, kleine GIST-achtige letsels die 
toevallig worden aangetroffen (<1 cm groot), komen veel frequenter voor namelijk in ten 
minste 30% van de oudere bevolking. Men denkt dat de cellen waaruit GIST ontstaan de 
interstitiële cellen van Cajal (ICC) zijn, dit zijn geïnnerveerde cellen die de peristaltiek van de 
darm reguleren. Men denkt dit aangezien beide celtypes afhankelijk zijn van de KIT tyrosine 
kinase receptor en aangezien ze dezelfde morfologie en hetzelfde immuun fenotype vertonen. 
Ongeveer 85% van de GIST hebben activerende mutaties in de KIT of PDGFRA genen, deze 
mutaties worden gezien als één van de eerste gebeurtenissen bij het ontstaan van GIST. 
Activatie van KIT of PDGFRA leidt tot constitutieve stimulatie van de RAS/RAF/MAPK, 
PI3K/AKT/mTOR en JAK/STAT signaaltransductiepaden. Deze signaaltransductiepaden zijn 
cruciaal voor de proliferatie, overleving en migratie van GIST cellen. Desalniettemin, hoewel 
oncogene mutaties in KIT/PDGFRA nodig zijn, zijn ze niet voldoende voor maligne 
transformatie tot GIST. Immers, micro-GIST hebben dezelfde KIT/PDGFRA mutaties, maar 
resulteren zelden in klinisch significante GIST. Dit geeft aan dat de oncogene evolutie van 
GIST vermoedelijk bevorderd wordt door extra genetische en epi-genetische veranderingen en 
dat GIST mogelijks gestimuleerd wordt door extra prikkels uit de omgeving. De biologische 
mechanismen en factoren betrokken bij deze meerstaps maligne transformatie zijn nog 
grotendeels onbekend. Gezien het feit dat de eerste- en tweedelijnsbehandeling van agressieve 
GIST met tyrosine kinase-remmers zoals imatinib of sunitinib zelden volledig succesvol zijn, 
is een betere kennis van de pathogenese van GIST noodzakelijk opdat nieuwe doelwitten voor 
therapie gevonden zouden kunnen worden, wat verder zou kunnen leiden tot de ontwikkeling 
van effectievere therapieën voor GIST. 
In dit proefschrift hebben we GIST uitgebreid gekarakteriseerd op cytogenetisch, moleculair 
en functioneel vlak. We hebben in het bijzonder onderzoek gedaan naar de relevantie van twee 
geselecteerde genen, CCK2R en PTEN, en hun bijdrage aan de ontwikkeling en progressie van 
GIST.  
CCK2R behoort tot de superfamilie van de G-proteïne gekoppelde receptoren. CCK2R wordt 
tot expressie gebracht in het maagdarmkanaal en medieert de werking van gastrine, regelt de 
maagzuursecretie en de groei en differentiatie van het maagepitheel. Eens gastrine 
gestimuleerd is, is CCK2R in staat om belangrijke signaaltransductiepaden, bijvoorbeeld PLC 
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en PKC, RAS/MAPK en PI3K/AKT, te activeren dewelke op hun beurt cel overleving, 
proliferatie en invasie bevorderen. Wat interessant is, is het feit dat geactiveerd CCK2R 
groeibevorderende effecten vertoond op pre-neoplastische gastro-intestinale cellen. 
Verschillende soorten kanker vertonen CCK2R expressie, maar CCK2R komt niet tot expressie 
in de overeenkomstige normale weefsels. Deze waarnemingen suggereren een mogelijke rol 
voor CCK2R in tumor pathogenese. In dit proefschrift hebben we aangetoond dat CCK2R 
expressie vooral voorkomt in GIST tumoren van maag oorsprong. Daarnaast zagen we een 
hoger niveau van CCK2R expressie bij GIST met weinig maligne potentieel in vergelijking 
met GIST met hoog risico/maligniteit, ongeacht het genotype van de tumor. We hebben 
bovendien CCK2R expressie aangetoond in gevallen van incidentele ICC hyperplasie en in 
micro-GIST in de maag. Daarnaast hebben we, via in vivo studies in muizen met humane GIST 
xenotransplantaten, aangetoond dat gastrine-afhankelijke stimulatie van CCK2R leidt tot 
verhoogde cel proliferatie en een groter tumorvolume. We hebben hyper-activatie van de PKC-
θ en KIT kinasen waargenomen en vervolgens over-activatie van grote downstream KIT 
signaaltransductiepaden (AKT en MAPK). Deze bevindingen suggereren een bevorderende rol 
voor gastrine en CCK2R in een vroeg stadium van GIST ontwikkeling, vooral in tumoren die 
ontstaan in de maag. 
Daarnaast hebben we in dit proefschrift gedeeltelijk of volledig verlies van PTEN expressie 
aangetoond in geavanceerde kwaadaardige GIST, dit vooral in tumoren die resistentie tegen 
imatinib vertoonden. Dit is in lijn met de gemeenschappelijke inactivering van cruciale tumor 
suppressor genen in de late stadia van GIST ontwikkeling. Verder hebben we aangetoond dat 
PTEN tekort vooral te wijten is aan het verlies van één alleel van het PTEN gen. PTEN is een 
proteïne fosfatase dat het PI3K/AKT signaaltransductiepad negatief reguleert. Na in vitro 
onderdrukking (silencing) van PTEN in GIST cellen, hebben we de over-activering van zowel 
de PI3K/AKT en de MAPK routes waargenomen die met elkaar zijn verbonden via een 
complex netwerk van crosstalk en teruggekoppelde signalen. Interessant is dat we resterende 
activatie van signaaltransductiepaden verantwoordelijk voor cel overleving hebben aangetoond 
na imatinib behandeling en paradoxale over-activatie van MAPK na remming van zowel PI3K 
als mTOR met NVPBEZ235. Gecombineerde behandelingen werkten de effecten van PTEN 
silencing op AKT en MAPK activatie met succes tegen in imatinib-gevoelige GIST cellijnen, 
terwijl aanzienlijke MAPK hyperfosforylering nog werd waargenomen in imatinib-resistente 
cellen. In dezelfde cel context zou gelijktijdige remming van de PI3K/AKT en RAS/MAPK 
routes moeten worden getest. Onze resultaten benadrukken het belang van het PTEN-
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deficiëntie bij GIST progressie. Bovendien blijkt PTEN een belangrijke biomerker om GIST-
patiënten te selecteren voor geschikte therapieën. 
Samengevat, CCK2R expressie en PTEN inactivering bevorderen de progressie van GIST in 
verschillende stadia en voorzien zo selectief voordeel aan de tumorcellen. In feite leidt de 
accumulatie van aberraties tijdens de maligne transformatie van GIST tot tumor heterogeniteit, 
wat de respons op de behandeling beïnvloedt.Een grotere kennis van de cruciale genen die 
betrokken zijn bij de evolutie van GIST zal leiden tot een vroegere diagnose, een betere 
prognose en meer doeltreffende behandelingen. 
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INTRODUCTION 
1. GIST history 
Gastrointestinal stromal tumours (GIST) are mesenchymal neoplasms of the digestive system. 
For decades, GIST have been erroneously diagnosed as smooth muscle tumours: leiomyomas, 
leiomyoblastomas, and leiomyosarcomas [1]. However, later studies using electron microscopy 
and immunohistochemistry demonstrated a lack of typical smooth muscle differentiation. In 
1983, GIST were first recognized as a distinct pathological entity by Mazur and Clark [2]. 
During the 1990s, several investigators noted similarities between GIST cells and interstitial 
cells of Cajal (ICC), which regulate the peristalsis of the bowel [3]. It was shown that ICC 
express KIT receptor (CD117), and its activity has a crucial role for their growth and function. 
This finding led to the ground-breaking discovery, by Hirota and colleagues in 1998, that GIST 
commonly overexpress CD117 and harbour mutations in KIT receptor tyrosine kinase (RTK) 
gene [4]. In 2003, Heinrich and colleagues identified platelet-derived growth factor receptor 
alpha (PDGFRA) gene mutations as an alternative pathogenic event in a small subset of GIST 
[5]. Simultaneously to the growing understanding of GIST tumour biology and driving 
oncogenic mechanisms, imatinib mesylate (Glivec, formerly STI-571; Novartis) was 
introduced into the clinic. This small molecule is a tyrosine kinase inhibitor (TKi), initially 
approved by the Food and Drug Administration (FDA) for the treatment of chronic myeloid 
leukemia (CML); entity characterized by the Philadelphia translocation (BCR/ABL fusion) [6]. 
A part from blocking abelson kinase (ABL), imatinib showed inhibitory activity towards KIT 
and PDGFRA kinases with high specificity [7-9]. Remarkable progresses have been made since 
GIST was an unknown and untreatable disease, refractory to all systemic therapies. Nowadays, 
a correct pathological and molecular classification of GIST is possible and patients with 
advanced inoperable tumours benefit from TKi treatment [10-12]. However, complete 
responses are rare and the majority of patients develop resistance to these agents [13]. GIST 
are regarded as a paradigm for molecularly targeted therapy and represent a model to study 
mechanisms of oncogenic progression, drug response and resistance. Future challenges are the 
understanding of GIST evolution and progression and the development of novel strategies for 
more effective therapies. 
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2. Epidemiology  
GIST are known to be the most frequent (70%) mesenchymal neoplasms of the gastrointestinal 
tract. Based on European studies, the annual incidence of clinically significant GIST is 
estimated at 12-14.5 per million inhabitants [14-15]. However, small incidental forms (<1 cm 
in size; microscopic GIST) are far more common, occurring in at least 30% of elderly 
individuals [16-17]. GIST can arise at any age, but typically occur in older adults, at a median 
age ranging between 55 and 65 years, without clear gender predilection. GIST can occur 
anywhere along the gastrointestinal tract, but they most commonly arise in the stomach (50-
60%) and small intestine (30–35%), and less frequently in the colorectum (5%) and oesophagus 
(<1%) [18-19]. Occasionally, GIST are found in sites of the abdominal cavity which are not 
related to the bowel wall (e.g. omentum, mesentery, retroperitoneum); these tumours are 
referred to as extra-gastrointestinal stromal tumours (E-GIST). Metastatic GIST often spread 
with multiple metastases to the peritoneum or the liver and rarely to the lungs, lymph nodes 
and axial bones. 
3. GIST origins and development 
3.1   ICC 
The ICC are located in the muscularis propria and around the Auerbach’s myenteric plexus. 
They are innervated cells that form a complex network throughout the gastrointestinal tract, 
serving as pacemakers for the peristaltic contraction of smooth muscles [20]. Strong evidences 
support the hypothesis that GIST arise from ICC, or a common mesenchymal progenitor. 
Firstly, ICC express KIT tyrosine kinase and are dependent on stem cell factor (SCF) for their 
development, function and proliferation [21]. KIT-deficient mice failed to produce functional 
ICC and manifested disruption of intestinal motility [22]. Vice versa, engineered mice carrying 
KIT activating mutations developed diffuse ICC hyperplasia within the muscular wall of the 
stomach and intestine and GIST-like tumours [23-25]. Furthermore, GIST and ICC share 
similar morphology and immunophenotype [3]. Both express DOG1 [26], CD34 [27], protein 
kinase C-theta (PKCƟ) [28-29] and ETS translocation variant 1 (ETV1). ETV1 was proposed, 
by Chi and co-workers, to be a lineage-specific transcription factor expressed by the myenteric 
and intramuscular subpopulations of ICC that are believed to give rise to GIST [30]. The 
possibility that GIST originate from a stem cells ICC precursor has been studied by Bardsley 
and colleagues [31]. They showed that murine multipotent ICC progenitors express DOG1, 
CD44, CD34, insulin receptor (Insr) and insulin-like growth factor 1receptor (IGFR1), and 
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only low level of KIT (KITlow). KITlow cells regenerate mature ICC and, in the presence of an 
activating KIT mutation, they likely represent a TKi resistant reservoir for GIST. Thus, GIST 
stem cells are only partially dependent on KIT, showing in addition an epithelioid morphology. 
Notably, these cells closely resemble a subpopulation of GIST cells in patients, occasionally 
de novo, but particularly after prolonged imatinib therapy [32-33]. Finally, ICC hyperplasia is 
found frequently in GIST familial syndromes, and is thus considered a precursor lesion of GIST 
[34]. 
3.2   MicroGIST 
Distinctive stage of GIST development is represented by GIST tumorlets, also referred to as 
minute GIST (< 5mm in size), microscopic GIST (< 1cm, micro-GIST) or milli-GIST (< 2cm). 
These subclinical forms of GIST are extremely frequent, being present in one third of the adult 
population worldwide [17]. Most GIST tumorlets remain asymptomatic for several years and 
most cases are detected only incidentally during imaging, endoscopy, surgery or autopsy for 
other reasons. For instance, micro-GIST are observed in up to 35% of gastro-oesophageal 
resections; likewise, minute GIST can be detected in the proximal stomach in 22.5% of 
autopsies of patients older than 50 years [16]. Interestingly, simultaneous occurrence of 
incidental GIST with other gastrointestinal malignancies (i.e. gastric cancer) has been observed 
with a frequency of 17.4% [35]. Field effect, where growth factors/mitogens are released by 
associated malignancies, could play a role in stimulating small GIST development [36]. In 
addition, GIST tumorlets were detected directly adjacent to clinically overt GIST, suggesting 
that these small incidental tumours are on a biological continuum with larger clinical lesions. 
As a matter of fact, subclinical and clinical GIST show similar morphology, mainly spindle 
cells, and share similar gene expression biomarkers [37]. Most importantly, micro-GIST 
harbour the same type of KIT/PDGFRA mutations at similar frequency as in clinically 
significant GIST [16-17]. These findings suggest that oncogenic mutations in these receptors 
occur very early in GIST tumorigenesis. However, even though KIT/PDGFRA mutations are 
most probably the initiating event in GIST development, they do not correlate with further 
disease progression or aggressive behaviour [17, 38]. Only a small subset of micro-GIST 
evolves towards clinically relevant tumours, while most of them regress into self-limiting 
lesions. They are found often mitotically inactive and frequently associated with hyalinization 
and calcification, suggesting tumorigenic arrest. These observations indicate that the oncogenic 
evolution of GIST can be arrested at several stages; whereas, additional genetic hits or 
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epigenetic and environmental stimuli are required to further progress to clinically significant 
tumours. 
4. Anatomical location and Microenvironment 
The anatomical location of primary GIST can determine the risk for progression towards 
malignant tumour behaviour. Indeed, GIST with non-gastric origin are usually more aggressive 
than gastric ones [39]. Moreover, GIST mutational status correlates closely with the anatomic 
tumour site. For instance, GIST which harbour KIT exon 9 mutations occur predominantly in 
the small intestine; whether those with PDGFRA mutations arise mainly in the stomach [40-
43]. It is assumed that these GIST originate from different subgroups of ICC. Notably, the 
transforming capabilities of different KIT mutations depend on the cell type affected [44]. KIT 
mutations have been found in other human malignancies; for example, KIT exon 17 mutations 
are frequently found in mast cell disease, seminoma and dysgerminoma, acute myeloid 
leukemia (AML) and CML, sinonasal natural killer and T-cell lymphoma [45]. Conversely, 
these mutations are uncommon in GIST, even though they are highly activating. On the other 
hand, oncogenic KIT exon 11 mutations, the KIT exon most frequently mutated in GIST, are 
common in melanoma but very rare in human mastocytosis.  
GIST can be found concurrent with other malignancies (i.e. gastric cancer) [46-47]. The 
synchronous neoplasms might influence GIST pathogenesis by releasing growth factors or 
affecting the common microenvironment. Usually, GIST develop in the sub-mucosal layer of 
the stomach surrounded by smooth muscle cells and interstitial extracellular matrix rich in 
collagen. It has been demonstrated that also GIST cells can modulate the surrounding 
microenvironment creating a permissive stroma. They secrete exosomes containing oncogenic 
KIT which are internalized by neighbouring stromal cells [48]. This leads to the activation of 
KIT downstream AKT and mitogen activated kinase (MAPK) signalling, in these cells, 
stimulates the secretion of matrix metalloproteinases and causes phenotypic changes of the 
tumour microenvironment, which promotes tumour cell invasion [49]. On the other hand, the 
surrounding microenvironment can support cancer progression and even create the conditions 
to induce oncogenesis. One hypothesis, introduced by Slaughter et al in 1953 [50], is the 
presence of a field cancerization, histologically abnormal tissue adjacent to a neoplastic area 
that predisposes to tumour formation. Moreover, immune cells around the tumour could 
determine whether the tissue environment permits tumour formation [51]. Finally, the cells of 
the organ where the tumour arise, release growth factors and mitogens as part of their 
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physiological function; simultaneously, they could also stimulate tumour progression. 
Intercellular communication is an important process during tumour development and 
progression and there are growing evidences of the reciprocal interplays between tumour cells 
and the surrounding microenvironment. However, more efforts are needed to identify specific 
biomarkers to facilitate the diagnosis, and essential targets for alternative or complementary 
therapies.  
5. The cholecystokinin 2/gastrin receptor (CCK2R) 
The Cholecystokinin 2/gastrin receptor (CCK2R) gene has been localized on human 
chromosome 11p15.4 and it is organized into five exons interrupted by 4 introns. CCK2R 
belongs to the superfamily of G protein-coupled receptors (GPCR), which are characterized by 
seven transmembrane α-helical domains, an extracellular NH2-terminal and an intracellular 
COOH-terminal ends [52]. CCK2R mediates important physiological functions by binding 
cholecystokinin (CCK) and gastrin peptides. It is widely expressed in the central nervous 
system, where it regulates anxiety/panic attacks, dopamine release, and nociception. CCK2R 
is also expressed in the gastrointestinal tract, in particular, it has been identified on parietal, 
enterochromaffin-like (ECL) and D cells within the gastric epithelium, where it controls gastric 
acid, histamine and leptin secretion as well as cell growth and differentiation [53-54]. More 
specifically, it mediates the action of gastrin. Gastrin is secreted by G cells in the gastric 
antrum, where it acts upon ECL cells to promote the release of histamine. Then, histamine 
interacts with parietal cells, which results in the up-regulation of surface H+/K+ proton pumps 
and stimulation of gastric acid secretion [55]. Gastrin can directly interact with parietal cells, 
as they express CCK2R. Additionally, gastrin promotes the maintenance of the gastric 
epithelium [53], by stimulating the proliferation of gastrin receptor-expressing ECL cells and 
mucous neck cells in the gastric mucosas, which can differentiate into parietal cells.  
Interestingly, CCK2R has been found to be expressed in different cancers of neuroendocrine 
origin, whereas it is not present in the corresponding normal tissues [56] and it is also expressed 
in many cancers of the gastrointestinal tract, such as colorectal carcinomas [57], metaplastic 
cells associated with Barrett’s esophagus [58], esophageal adenocarcinomas [59], pancreatic 
[60] and gastric cancers [61]. CCK2R is highly expressed in GIST [62]. Notably, CCK2R is 
implicated in a wide variety of signal transduction pathways leading to gastric acid secretion 
but also motility, invasion, inflammation, proliferation, and survival, all factors that promote 
cancer development and progression (Figure 1).  
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Figure 1 (adapted from Dufresne and colleagues [52]). Graphic illustration of selected and simplified signalling 
cascades downstream of CCK2R. CCK2R activation promotes transcription, proliferation, growth, survival and 
motility.  
After ligand binding, CCK2R activates heterotrimeric G protein of the Gq family, resulting 
into the Gαq and Gβγ subunit dissociation and the exchange of guanosine disphosphate (GDP) 
for guanosine triphosphate (GTP) on Gαq. The resulting GTP-Gαq complex, in turn, activates 
the phospholipase C (PLC), which catalyses the hydrolysis of phosphatidyl inositol 4,5-
bisphosphate (PIP2) in the plasma membrane to produce two second messengers: inositol 
1,4,5-trisphosphate (IP3) and 1,2,-diacylglycerol (DAG). IP3 binds to its intracellular receptor, 
a ligand-gated Ca2+ channel located in the endoplasmic reticulum, and triggers the release of 
Ca2+ from internal stores. Increased concentration of Ca2+ and/or DAG activates α, β, γ, δ, ε, η, 
and θ isoforms of protein kinase C (PKC), a family of a serine/threonine kinases [52]. CCK2R 
activates Src family kinases that in turn, and dependent on PKC, phosphorylate Src homolog 
(SH) domain containing protein (Shc), enabling it to complex with growth factor receptor 
bound 2 (Grb2) and son of sevenless (Sos) [63-64]. This complex then activates the 
RAS/RAF/MAPK/extracellular signal regulated kinase (ERK) cascade, and the phosphatidyl 
inositol 3 kinase (PI3K)/AKT pathway in parallel [65-66]. Also the Janus kinase (JAK)/ signal 
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transducers and activators of translations (STAT) pathway and focal adhesion kinase (FAK) 
protein are activated upon CCK2R stimulation [67-68]. These pathways are fundamental in 
GIST pathogenesis (described below in more details). Noteworthy, it has been demonstrated 
that PKCƟ activation is crucial for GIST cell survival and proliferation and it regulates KIT 
expression [69].  
A CCK2R splice variant, CCK2Ri4sv, has been reported in colorectal and pancreatic cancers, 
and in Barrett’s metaplasia [58, 70, 71]. CCK2Ri4sv has the fourth intron inappropriately 
retained. The molecular basis for this miss-splicing event is explained by a weak 3’ splice site 
of intron 4 of the CCK2R in association with reduced splice factor levels [71]. Retention of 
intron 4 leads to insertion of an additional 69 amino acids in the third intracellular loop of the 
CCK2 receptor protein, a domain important for the signal transduction. CCK2Ri4sv results to 
be constitutively active and continuously activates Src kinase and AKT [58, 72].  
All in all, CCK2R has been shown to have growth-promoting effects on pre-neoplastic 
gastrointestinal cells of epithelial origin when stimulated by gastrin. Hypergastrinemia caused 
by proton pump inhibitors (PPi), H2 receptor antagonists or resection of the acid-secreting 
mucosa, promotes ECL hyperplasia and leads to a thicker gastric and colonic mucosa. 
Moreover, increased gastrin level is associated with colorectal carcinogenesis, and in the 
presence of Helicobacter pylori leads to gastric cancer. Whether gastrin represent one of the 
growth promoting factor released by the microenvironment able to stimulate GIST 
development needs to be determined.  
6. Driving oncogenic mutations 
6.1 KIT 
The human KIT gene is located on chromosome 4q12-13 and it is organized in 21 exons. It 
encodes for a transmembrane glycoprotein which belongs to the type III RTK family. Members 
of the same family are the PDGFRA and PDGFRB, the macrophage colony-stimulating-factor 
receptor (CSF1R) and the Fl cytokine receptor (FLT3) [73]. These kinases are composed of an 
extracellular (EC) domain containing five immunoglobulin-like repeats, a transmembrane 
sequence, followed by a juxtamembrane (JM) region and two cytoplasmatic tyrosine kinase 
(TK) domains, the ATP-binding pocket (TK1) and the phosphotransferase region (TK2) 
(Figure 2) [73].  
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Figure 2. Schematic structure of KIT/PDGFRA tyrosine kinase receptors. Under physiological conditions, SCF 
binding to the EC domain leads to receptor dimerization and progressive phosphorylation of several key tyrosine 
residues, resulting in complete KIT/PDGFRA activation. On the left, hot spot sites of primary KIT and PDGFRA 
mutations and relative frequency. 
KIT ligand, the SCF, is a cytokine encoded by a gene that maps to chromosome 12q22-24 [74]. 
Under physiological conditions, binding of SCF to KIT EC domain results in receptor 
dimerization and activation of its intrinsic kinase activity, whereas the JM domain inhibits KIT 
kinase activity in the absence of KIT ligand. Stimulation of KIT receptor triggers a 
phosphorylation cascade of the tyrosine residues in multiple downstream signalling molecules 
[75]. This leads to the activation of signal transduction pathways involved in cell proliferation, 
apoptosis, metabolism, migration and differentiation. The PI3K/AKT/ mammalian target of 
rapamycin (mTOR) pathway, the RAS/RAF/MAPK pathway and the JAK/ STAT pathway are 
the most crucial ones [74]. KIT activity is critical for the development and the biology of 
different cell types, such as haematopoietic cells, mast cells, melanocytes, gametocytes and 
ICC [76-77]. Deregulation of the SCF/KIT pathway has been observed in different human 
cancers. In small cell lung carcinomas, colorectal carcinoma, breast carcinoma, gynaecological 
tumours, and neuroblastomas, autocrine secretion of SCF results in KIT over expression and 
sustained cell proliferation [73]. Moreover, as mentioned before, oncogenic KIT mutations 
have been reported in seminomas, melanomas, mastocytosis and AML [73].  
Gain-of-function KIT mutations are considered initiating event in GIST development and they 
are present in 70-80% of the patients with this disease [4, 19]. Several evidences highlight the 
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important role of KIT oncogenic mutations in GIST pathogenesis. Almost all GIST specimens 
and GIST cell lines show KIT phosphorylation. Mutant KIT is transforming, promoting the 
growth of stably transfected BA/F3 cells in nude mice, and its kinase activity is constitutive 
activated in the absence of SCF when expressed in transfected cell lines [4, 78]. As mentioned 
before, genetically modified mice expressing KIT mutants develop diffuse ICC hyperplasia of 
the stomach and intestine and GIST-like tumours [34]. Notably, KIT inhibition decreased 
proliferation and induced apoptosis in GIST cell lines and in primary GIST cell cultures. 
Finally, GIST cells under TKi treatment develop secondary KIT mutations that confer drug 
resistance but maintain the kinase activity, required to sustain the tumour even in the advanced 
stage of the disease [79-83]. 
In GIST patients, different type of mutations in KIT gene have been observed, being mostly 
non-random in-frame mutations (point mutation, deletions or duplications) [19]. Primary KIT 
gain-of-function mutations occur mainly in the regulatory subunit and at lower frequency in 
the enzymatic domain; resulting in the disruption of the structure of the receptor and subsequent 
ligand-independent activation of its kinases. This leads to a constitutive activation of the 
signalling cascades, which stimulates uncontrolled cell proliferation and survival [84-85].  
The most common mutations affect the JM domain (70%), encoded by exon 11. They include 
point mutations, deletions or insertions which disrupt the integrity of its auto-inhibitory 
function [86]. Mutations in the EC domain (10%), encoded by exon 9, include mainly tandem 
duplication of residues alanine 502 and tyrosine 503. EC oncogenic mutations are believed to 
mimic the conformational change that the extracellular KIT receptor undergoes after ligand 
binding by modifying a portion of KIT protein, which is relevant for the dimerization of the 
receptor. This results in enhanced binding affinity towards adjacent KIT receptors [87]. 
Mutations in the TK domain, in the ATP-binding region and in the activation loop, encoded by 
exon 13 and exon 17, respectively, are uncommon (1-2%) in GIST not previously exposed to 
TKi treatment. They are mostly caused by single nucleotide substitutions [84]. Mutations in 
the TK1 domain might lead to spontaneous KIT homodimerization, whereas TK2 mutations 
enhance KIT protein autophosphorylation and stabilize its active conformation [85]. 
6.2 PDGFRA 
The human PDGFRA gene cluster together with KIT on chromosome 4q12-13 and consists of 
23 exons. PDGFRA tyrosine kinase also belongs to the type III RTK family and shares high 
homology structure with KIT receptor (Figure 2) [5]. Platelet derived growth factors (PDGF) 
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are a family of dimers able to bind and activate PDGFRA. Ligand binding induces receptor 
dimerization and tyrosine phosphorylation, which activates the receptor kinases and triggers a 
number of downstream signal transduction pathways similar to KIT activation [88]. It has been 
shown that PDGFRA regulates the migration and proliferation of smooth muscle cell 
progenitors and it is important during intestinal development [89]. PDGFRA is expressed in 
erythroid and myeloid precursors in bone marrow, as well as monocytes, megakaryocytes, 
fibroblasts, endothelial cells, osteoblasts, glial cells and smooth muscle cells. PDGFRA was 
found to be involved in different types of cancers, such as glioblastoma, some types of 
leukaemia and sarcomas [90]. Genomic aberration of PDGFRA includes activating mutations, 
amplification and translocation.  
In GIST, about 7-14% of cases present mutations in the PDGFRA gene. PDGFRA mutations 
in GIST include point mutations, insertions or deletions. They affect PDGFRA domains that 
are equivalent to those mutated in KIT, as the TK2 (95%, encoded by exon 18), the TK1 (1%, 
exon 14) and the JM domain (1-2%, exon 12) [84, 91]. These mutations result in the 
constitutive ligand-independent activation of PDGFRA leading to excessive cell proliferation 
and resistance to apoptosis. The KIT and PDGFRA mutations are mutually exclusive events in 
GIST. Nevertheless, approximately 30% of KIT-mutants also express wild-type PDGFRA, 
whereas PDGFRA-mutants often show low or lack of KIT expression. Overall, KIT and 
PDGFRA-mutant GIST share many similar features. They show similar immuno-phenotype, 
they undergo to similar cytogenetic changes and they activate the same signalling pathways. 
Nevertheless, differences in prevalent anatomic site, morphologic subtypes and gene 
expression profiling have been observed, which may reflect a slightly different tumour biology 
and explain their diverse clinical behaviour; PDGFRA-mutant GIST represent mainly gastric 
tumours with low or no malignant potential [42, 62]. 
6.3 Familial GIST Syndromes associated with germ-line KIT/PDGFRA mutations 
Hereditary GIST syndrome is a rare autosomal dominant disorder characterized by germline 
gain-of-function KIT mutations and in rare cases by PDGFRA mutations [34]. Heritable 
mutations in KIT exon 8, 11, 13, 17 and in PDGFRA exon 12 and 18 have been reported; these 
mutations are in general structurally similar to those observed in sporadic tumours. Affected 
patients have a high risk to develop ICC hyperplasia and multiple GIST at relatively young 
age. Additional clinical features, related to other KIT-dependent cells, have been associated to 
familial GIST syndrome, such as dysphagia, skin hyperpigmentation, urticaria pigmentosa and 
mastocytosis [84]. 
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6.4    KIT/PDGFRA-wild type GIST 
The KIT/PDGFRA oncogenic mutations define the typical genetic drivers in GIST 
pathogenesis, being observed in up to 85% of cases. The remaining 15% show neither KIT nor 
PDGFRA mutations, and are referred to as KIT/PDGFRA “wild-type” GIST (WT-GIST) [84]. 
They represent a heterogeneous group and display various genomic aberrations.  
A subset of GIST harbours mutations that involve the RAS/RAF/MAPK signalling pathway. 
BRAF V600E substitution, commonly observed in melanoma and papillary thyroid carcinoma, 
can be found in 7-15% of WT-GIST, although it can be also observed in 2% of KIT/PDGFRA 
mutant GIST [92-95]. Primary KRAS, HRAS and NRAS mutations are rare events in GIST [94]. 
Moreover, approximately 7% of patients affected by neurofibromatosis type I (NF1, also 
known as von Recklinghausen disease) develop one or multiple GIST, in majority 
KIT/PDGFRA wild-type. NF1 gene encodes for the protein neurofibromin and functions as a 
tumour suppressor gene by negatively regulating the RAS pathway. NF1 disease is inherited 
as an autosomal dominant disorder and NF1 related GIST show either somatic mutation or loss 
of the remaining NF1 wild-type allele. Typically this subset of tumours still express KIT and 
CD34, arise mainly in the intestine, may undergo similar genomic aberrations as 
KIT/PDGFRA-mutant GIST and tend to rely on the hyper-activation of the MAPK pathway 
[96].  
Another subgroup of WT-GIST, succinate dehydrogenase (SDH)-deficient GIST, show defects 
in the SDH complex, which oxidizes succinate to fumarate as part of the Kreb’s cycle. The 
SDH complex is composed of proteins encoded by SDHA, SDHB, SDHC, and SDHD genes, 
and belongs to the mitochondrial tumour suppressor gene pathway. SDH loss-of-function leads 
to succinate accumulation, which may negatively regulate prolyl hydroxylase. This enzyme 
controls the hypoxia-inducible factor 1α (HIF1α) level, and HIF1α is a transcriptional activator 
of insulin-like growth factor 2 (IGF2), vascular endothelial growth factor (VEGF), 
transforming growth factor alpha (TGFα) and PDGF [97]. IGF2 overexpression can activate 
IGFR1 in an autocrine manner. Accumulation of succinate also inhibits the TET family of 
DNA hydroxylases, which catalyse the conversion of 5-methylcytosine to 5-
hydroxymethylcytosine (5-hmC), required for subsequent DNA de-methylation. TET-
mediated 5-hmC production alters global DNA methylation patterns and influences gene 
expression. Approximately 7.5% of gastric WT-GIST show SDHB-deficiency by 
immunohistochemistry, regardless of which SDH subunit is affected [98]. Most of these cases 
occur in children and young adults, with predilection for female gender. They usually show a 
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multinodular growth pattern, frequently metastasise to the lymph nodes, and in general show 
expression of KIT, DOG-1 and CD34. Majority of these patients harbour germline mutations 
in SDHA, SDHB, SDHC or SDHD. These mutations are underlying mechanisms in patients 
affected by the Carney-Stratakis syndrome, which is characterized by autosomal dominant 
inheritance of SDH-deficient WT-GIST and paragangliomas [99]. GIST that arise in this 
context, show either loss or somatic mutations of the remaining SDH wild-type allele [100]. 
Recently, loss-of-function defect in the mitochondrial SDH complex due to recurrent 
epimutation of SDHC was reported in SDH-deficient GIST in individuals affected by the 
Carney’s triad [101]. The latter is a rare non-heritable syndrome that is seen mainly in girls and 
young women, who are at high risk to develop gastric WT-GIST, paraganglioma, and 
pulmonary chondroma. Around 50% of SDH-deficient GIST shows high expression of IGFR1; 
this signals through both, the MAPK and the PI3K-AKT pathways. Notably, these tumours 
cluster separately from KIT/PDGFRA mutant GIST by gene expression profiling and tend to 
progress to malignancy without acquiring gross chromosomal aberrations.  
In the remaining WT-GIST the underlying biological mechanism is yet to be established. 
7. GIST signalling  
Constitutive phosphorylation of KIT triggers a cascade of downstream signalling through the 
activation of the RAS/RAF/MAPK, PI3K/AKT/mTOR and JAK/STAT pathways (Figure 3) 
[44, 74]. These pathways modulate cell proliferation, survival, differentiation, metabolism and 
migration. The JAK/STAT pathway is known to play only a marginal role in GIST 
pathogenesis, whereas the RAS/RAF/MAPK and the PI3K/AKT/mTOR pathways are both 
crucial for proliferation in GIST and offer potential therapeutic targets. 
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Figure 3. Simplified scheme of KIT/PDGFRA downstream signalling. Stimulatory interactions are indicated by 
green arrows and inhibitory interactions by red -|. KIT/PDGFRA activation promote transcription, proliferation, 
growth and survival. 
7.1 RAS/RAF/MAPK pathway 
Upon receptor dimerization and autophosporylation of its specific tyrosine residues at the 
cytoplasmic side, binding spots for the adaptor protein Grb2 and Shc are created. Grb2 interacts 
with the phosphorylated tyrosine on the receptor with its SH2 domain, or indirectly through 
Shc, and recruits Sos1 to form a complex through its SH3 domain. Sos1 is a RAS-guanine 
nucleotide exchange factor, through which GDP is exchanged for GTP on RAS, a GTP-binding 
protein. This exchange activates RAS. The tumour suppressor NF1 is a GTPase activating 
protein (GAP), which antagonizes RAS activation. GTP-bound RAS forms a complex with 
RAF1, a serine/threonine kinase, and stimulates its translocation towards the plasma 
membrane. RAF in turn activates mitogen-activated kinase kinase kinase (MEK) by 
phosphorylation of the serine residue in its activation loop. MEK subsequently activates 
ERK1/2 proteins. Activated ERK1/2 translocate to the nucleus, where they can phosphorylate 
a variety of substrates. For instance, they induce MYC and ELK1, which lead to changes in 
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gene expression. In addition, activation of p90RSK by ERK activates CREB, which increases 
transcriptional activity of FOS and JUN, cell cycle regulators, and downregulates capicua, 
which is a transcription suppressor of ETV1. Since ERK inhibits proteasomal degradation of 
ETV1, its activation by KIT results in an increase in ETV1. ETV1 is an essential transcription 
factor, member of the ETS family that regulates the lineage-specific gene expression program 
characteristic of ICC and GIST [30, 102]. Activating KIT mutations trigger the development 
of GIST from ICC with high ETV1 levels and initiate an oncogenic ETS transcriptional 
program. The activation of all these transcription factors contributes to the regulation of 
different processes such as cell proliferation, differentiation, migration and apoptosis.  
7.2 PI3K/AKT/mTOR pathway 
Alternatively, the binding of the SH2 domain on the regulatory subunit p85 of PI3K, direct or 
through adaptor proteins, to the phospho-tyrosine site on the activated KIT receptor relieves 
the intermolecular inhibition of the PI3K catalytic subunit p110. The PI3K is now localised on 
the plasma membrane where it can phosphorylate PIP2 to yield phosphatidylinositol 3,4,5 
trisphosphate (PIP3). The tumour suppressor phosphatase and tensin homolog deleted on 
chromosome 10 (PTEN) dephosphoryates PIP3 to PIP2, thereby negatively regulates the PI3K 
signalling. PIP3 is required for membrane localization of two pleckstrin homology (PH) 
domain-containing serine/threonine kinases, phosphoinositide-dependent kinase 1 (PDK1) and 
AKT (encoded by the protein kinase B or PKB genes). Here AKT undergoes conformational 
changes, which expose two of its crucial residues, a threonine (T308) and a serine (S473), for 
phosphorylation. The T308 is phosphorylated by PDK1, whether S473 is currently thought to 
be phosphorylated by mTOR rictor complex (mTORC2). Once phosphorylated, AKT is fully 
activated and can phosphorylate a wide number of proteins, hereby regulating many cellular 
processes such as protein synthesis, cell proliferation and cell survival. In particular, AKT 
promotes cell growth by activating mTOR in the mTORC raptor complex (mTORC1) [103]. 
AKT phosphorylates and inactivates the GAP TSC2 [104], which forms a complex with TSC1 
to inhibit a small GTPase, Ras-homolog enriched in brain (Rheb) [105]. Rheb inhibits FKBP38, 
a negative regulator of mTORC1 [106]. Alternatively, AKT phosphorylates and inhibits 
proline-rich AKT substrate of 40 KDa, which negatively regulates the activity of mTORC1 
competing with the GTPase Rheb. mTORC1 main downstream targets are the ribosomal 
protein S6 kinase 1 (S6K1, also known as p70S6 kinase) and the eukaryotic translation 
initiation factor E4-binding protein 1 (4EBP1). mTORC1 phosphorylates and activates S6K1 
[107], which in turn activates the ribosomal protein S6, the eukaryotic initiation factor 4B 
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(eIF4B) and other substrates [108-110]. Conversely, mTORC1 phosphorylates and inactivates 
4EBP1, releasing the inhibition of eIF4E [107]. Thus, mTORC1 promotes protein translation. 
PI3K mutations have been reported in one KIT-mutant GIST case.  
7.3 PTEN 
The phosphatase and tensin homolog (PTEN) gene maps on human chromosome 10q23.3, and 
it encodes a dual-specificity protein phosphatase that can act on both polypeptide and 
phosphoinositide substrates. Normally, human PTEN protein consists of 403 amino acids. It is 
composed of an N-terminal domain, which contains the enzymatic and the cellular localization 
subunits, a C2 lipid binding domain, and a PDZ binding motif for protein interaction at the C-
terminal. Recently, a translational variant of PTEN that accounts for 576-amino acids has been 
identified and named PTEN-Long [111-112]. Interestingly, PTEN-Long phosphatase can be 
secreted into the extracellular environment and internalized by recipient cells; here it acts as a 
tumour suppressor, like the classical PTEN.  
The major function of PTEN is to antagonize the PI3K signalling cascade. As previously 
mentioned, PTEN hydrolyzes PIP3 to generate PIP2, thereby preventing the PIP3-mediated 
activation of downstream signalling effectors such as PDK1 and AKT [113-114]. 
Consequently, PTEN is able to suppress and control the most critical cellular processes for 
cancer development and progression, including proliferation, survival, growth and metabolism. 
Moreover, it has been demonstrated that PTEN negatively regulates c-Jun N-terminal kinase 
(JNK) pathway [115] and inhibits MAPK [116], FAK [117], CREB and Src proteins. Recently, 
PTEN was found to be involved in the regulation of genomic instability, DNA repair, stem cell 
self-renewal, cellular senescence, cell migration and metastasis [118].  
PTEN protein can be found in both the cytoplasm and nucleus, and it is thought to be 
constitutively expressed in normal tissue. However, PTEN expression and function can be 
positively and negatively regulated at different levels, especially in pathological settings. PTEN 
function and expression can be altered by genetic mutations, insertions and deletions 
throughout the whole gene. Monoallelic or complete genetic loss of PTEN is also frequently 
observed in different cancers. In addition, PTEN transcription is regulated by a complex system 
that involves oncoproteins and tumour suppressors regulated in turn by PTEN itself, underlying 
an important network of feedback loops and cross-talks. For example, p53 induces PTEN 
expression by binding to PTEN promoter [119] and PTEN reduces p53 degradation. PTEN 
mRNA expression can be up-regulated also by the peroxisome proliferation-activated receptor 
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γ [120], the early growth-regulated transcription factor-1 [121], resistin, sprouty homolog 2, 
follicle-stimulating hormone and more other factors. On the other hand, PTEN transcription is 
negatively regulated by the PI3K pathway, through NEDD4-1 [122], by the RAS-MAPK 
pathway [123], through c-Jun [124] and TGFβ [125], as well as by JNK pathway, through 
MEKK4 and NFκB [126] and by NOTCH1 through MYC. Transcriptional repression of PTEN 
can be also mediated by epigenetic silencing through promoter methylation or histone 
deacetylation [127-130]. PTEN protein expression is controlled post-transcriptionally by 
microRNAs (miRNA), a class of small non-coding RNA able to repress mRNA translation by 
binding the 3′ untranslated region of the target mRNA. It has been reported that miR-494 [131], 
miR-21 [132], miR-19 and miR-221/222 down-regulate PTEN expression. Nevertheless, 
Pandolfi and colleagues, in their competing endogenous RNAs (ceRNA) model, demonstrated 
that the PTEN pseudogene 1 (PTENP1), which shares high sequence homology with PTEN, 
can act as a sponge for PTEN-targeting miRNA and limit their negative effect on PTEN 
expression [133]. At the protein level, PTEN undergoes post-translational modifications that 
regulate its activity, stability, conformation and subcellular localization. These changes can 
occur by PTEN phosphorylation, acetylation, oxidation, ubiquitination and by interaction with 
other proteins [134-138].  
Interestingly, even though PTEN is recognized to be a tumour suppressor gene, it does not 
always follow the ‘two-hit’ hypothesis postulated by Alfred Knudson’s in 1971, i.e. “mutation 
or deletion of one allele induces cancer susceptibility (the first hit) and mutation or loss of the 
other allele induces cancer (the second hit)”. As a matter of fact, a number of cancers present 
only monoallelic inactivation of the PTEN gene and retain one functional wild-type allele. 
Though, some of these tumours show complete loss of PTEN protein expression [139-142]. In 
these cases, PTEN negative regulation through one of the mechanisms described above could 
be involved. For example, methylation of the PTEN promoter is observed in thyroid cancer 
[143], melanoma [130], lung cancer [144] and low grade/secondary glioblastoma mulitforme 
tumours [145]. Nevertheless, in some cancers partial reduction of PTEN protein expression can 
still promote tumorigenesis. For instance, PTEN germline heterozygous aberrations are related 
with the development of a group of syndromes known as PTEN hamartoma tumour syndromes, 
like the Cowden’s syndrome [146-147]. Patients affected by this disease are at risk to develop 
different kind of cancers, including cancers of the breast, thyroid and uterus [148-149]. 
Moreover, monoallelic loss or mutations of PTEN are found in the 50-80% of endometrial 
carcinoma, glioblastoma, and prostate cancer and in the 30%–50% in breast, colon, and lung 
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tumours [150]. In mice, it has been demonstrated that deletion of one PTEN allele leads to the 
development of lethal autoimmune disorders and various forms of epithelial cancers [151]. 
Similar results were obtained from Alimonti and colleagues using PTEN hypermorphic mice; 
they found that subtle reductions in the dose of PTEN predispose to tumorigenesis [152]. All 
these evidences support the hypothesis that PTEN is functionally haploinsufficient, i.e. the 
amount of protein produced from the remaining wild-type allele is not sufficient for normal 
cellular function. More specifically, PTEN displays the property of ‘obligate haplo-
insufficiency’, where the heterozygous state might promote cancer to a greater degree than the 
homozygous state. One explanation is that complete loss of PTEN expression triggers a p53-
dependent senescence response that opposes tumour progression [153]. Therefore, some 
tumours may select for partial loss of function of PTEN in their initial steps of tumorigenesis.  
Notably, in some tumours PTEN deficiency has been associated with resistance to anticancer 
drugs, especially TKi and their pathways. For instance, it has been shown that PTEN loss 
confers resistance to the anti- HER2 antibody trastuzumab in breast cancer, and lowers the 
sensitivity to epidermal growth factor receptor (EGFR) inhibitors in glioblastoma, colon and 
lung cancer [154-157]. PTEN is the crucial antagonist of the PI3K/AKT pathway and PTEN 
insufficiency results in the upregulation of this signalling cascade. Hence, a rational solution 
to overcome PTEN-induced resistance to anti-RTK therapy might be a combinatorial therapy 
targeting both the RTK and the PI3K pathway. TKi against KIT and PDGFRA tyrosine kinase 
receptors represent the first line treatment for GIST patients. However, the majority of GIST 
patients eventually develop resistance to these drugs. As previously mentioned, the 
PI3K/AKT/mTOR signalling pathway is one of the major route for GIST progression and it 
could represent a valuable target for GIST treatment. Thereby, it becomes important to 
understand the role and the status of PTEN in GIST development to design a better-tailored 
therapy for GIST patients.  
7.4 JAK/STAT pathway 
In general, upon receptor stimulation and dimerization, two JAK molecules are brought into 
close proximity and activated. Activated JAK phosphorylates STAT and other downstream 
effectors. JAK and STAT signalling proteins are known to be relevant in mast cell disease 
harbouring KIT mutations. STAT activation in GIST can be JAK dependent or independent; 
however, this activation is most likely not crucial to GIST survival and proliferation. STAT1 
and STAT3 isoforms have been found to be express and activated in GIST, and it has been 
demonstrated that they promote JUN transcription.  
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7.5 Feedback loops and Cross-talks  
The PI3K/AKT/mTOR and the RAS/RAF/MAPK pathways are regulated by negative 
feedback loops, and are related to each other by several cross-talks (Figure 4).  
 
Figure 4. Graphic illustration of selected PI3K/AKT/mTOR and RAS/RAF/MAPK pathways negative feedback 
loops and cross-talks. Stimulatory interactions are indicated by green arrows and inhibitory interactions by red -|. 
PI3K activation is often mediated by adaptor proteins. An example is the insulin receptor 
substrate (IRS), which mediates the binding between the receptor and the PI3K regulatory 
subunit. It has been demonstrated that IRS is involved in the regulation of the PI3K pathway. 
In particular, the downstream target of mTORC1, S6K1 is able to phosphorylate and inhibit 
IRS-1, generating a negative feedback loop in the PI3K/AKT/mTOR pathway [158]. This 
finding becomes of extreme importance during therapies with mTORC1 inhibitors, such as 
rapamycin. Treatment with this drug leads to an unexpected reactivation of AKT and 
downstream effectors. Moreover, Carracedo and colleagues showed that the S6K—IRS1–PI3K 
feedback loop modulates also the RAS/MAPK pathway, as treatment with RAD001 
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(rapamycin analogue) leads to activation of MAPK. This is possibly due to the activation of 
RAS by PI3K [159]. Conversely, RAS can mediate PI3K activation by binding of the GTPase 
to the Ras-binding domain of PI3K [160]. As a matter of fact, the RAS/RAF/MAPK and the 
PI3K/AKT/mTORC1 pathways can interfere with each other at different levels. AKT can 
directly phosphorylate and inhibit C-RAF and B-RAF [161-162]. The small GTPase Rheb also 
regulates RAF [163]; whereas PDK1 and GSK3 inhibit MEK and ERK kinases, respectively 
[164-165]. Lastly, PTEN inhibits MAPK through the negative regulation of integrin signalling 
[116]. Overall, the PI3K pathway is able to reduce the activity of MAPK signalling. On the 
other hand, PTEN transcription is negatively regulated by MAPK [166]. Moreover, mTORC1 
complex is also regulated by MAPK in two different ways. Both p90RSK1 and ERK can 
phosphorylate and inhibit TSC2, at Ser1798 and at Ser664, respectively; this promotes 
mTORC1 activation [167-168]. In addition, p90RSK, as S6K, can also phosphorylate and 
activate the ribosomal protein S6 and eIF4B, promoting protein translation [169]. All in all, 
PI3K and MAPK signals both converge downstream of mTORC1. In conclusion, the 
complexity of the PI3K/AKT/mTOR and RAS/RAF/MAPK signalling enhanced by the 
intricacy of feedback loop and cross-talks that regulate them, stress the importance of a well-
designed treatment strategy when targeting these pathways.   
8. GIST progression 
Although oncogenic KIT/PDGFRA mutations are considered primary events in GIST 
pathogenesis, additional genomic alterations are required for their malignant transformation 
and clinical progression. At the early stage GIST present a relatively simple karyotype, often 
characterized by loss of chromosome 14q. During the evolution toward malignancy, GIST 
tumours accumulate progressively at least three genetic aberrations [13]. Loss of chromosome 
22q is associated with intermediate malignancy; whereas in the high risk and metastatic cases 
chromosomal imbalances, including -1p, -9p, -10, -11p, -13q, -15q and +5p, +8q, +17q, +20q, 
can be observed [170-173]. Crucial oncogenes or tumour suppressor genes that map to these 
chromosomes might be involved during tumour evolution, which could enhance tumour 
malignant behaviour and promote ulterior chromosomal instability. Despite the awareness of 
the specific minimal overlapping chromosome regions lost in GIST, the discovering of possible 
candidate genes involved in GIST progression remains elusive.  
Approximately two-third of GIST present either monosomy 14 or partial loss of 14q. Two 
recurrently deleted regions are 14q11.2 and 14q23.1-24.3. Most likely these loci harbour 
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tumour suppressor genes that play a role in early GIST development, such as PARP2, APEX1, 
NDRG2 and PPP2R5E, MLH3, RAD5IL, MAX, respectively. Interestingly, it has been shown 
that loss of chromosome 14 could influence to some degree GIST expression profile [174]. 
Moreover, Wozniak and colleagues observed that the expression of three specific genes on 
chromosome 14, i.e. MAX, MLH3 and HEI10, was significantly lower in the group of GIST 
with chromosome 14 loss in comparison with tumours with 14q disomy. MAX protein, alone 
or together with MYC, acts as a transcriptional regulator. MLH3 is a DNA mismatch repair 
protein, important to maintain genomic integrity during DNA replication [175]. HEI10 
negatively regulates cyclin B levels, causing delayed entry into mitosis [176]. Downregulation 
of MAX could change GIST gene expression profile from the early stages of the tumour 
development, low levels of MLH3 could enhance the accumulation of genomic alterations, and 
lack of HEI10 could stimulate cell proliferation.  
Almost half of GIST cases show loss of the long arm of chromosome 22, which is associated 
with progression to a borderline or malignant lesion. Minimal overlapping region containing 
possible hits (SMARCB1, CHK2, DEPDC5 genes) is the 22q11-q12. In contrast to losses of 
14q, deletions of 1p and 15q are associated with intestinal location, increased cytogenetic 
complexity, and a more aggressive clinical course. Hot spot regions for putative tumour 
suppressor genes have been identified on chromosome 1, namely 1p36.32- 1p35.2 (containing 
TP73 and DR3 genes), 1p34.1-1p34.1, and 1p22.1-1p21.3, and on chromosome 15q23 
(TMEM84 gene). Losses of 1p and 15q often coexist [173].  
A target of chromosome 9p loss is the CDKN2A (p16INK4A) gene, which encodes an important 
cell cycle regulator. The p16 gene is commonly inactivated in malignant GIST through 
deletion, either biallelic or in combination with mutation or promoter hypermethylation. 
Another crucial tumour suppressor gene, RB1, could be the target of partial losses of 13q14, as 
PTEN by losses of chromosome 10. On the other hand, gains on chromosomes 8q (on which 
MYC maps) and 17q are associated with clinically advanced tumours. Finally, in a recent study, 
Wang and co-workers have demonstrated that dystrophin [protein coded by Duchenne 
Muscular Dystrophy (DMD) gene, which maps on chromosome Xp21], is utterly inactivated 
during GIST progression [177]. In tumours of myogenic origin, like GIST, DMD acts as a 
tumour suppressor gene, and inhibits cell migration, invasion, anchorage independence and 
invadopodia formation. To note, GIST harbouring primary NF1, BRAF or KRAS mutations 
show a similar cytogenetic profile as KIT/PDGFRA mutants. Overall, the model of GIST 
progression is characterized by subsequent accumulation of chromosomal changes. This is true 
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for GIST that harbour kinase mutations, whereas SDH-deficient GIST have been shown to 
exhibit a lower level of cytogenetic complexity, implying a different mechanism of tumour 
progression [178].  
9. Clinicopathological features and diagnosis of GIST  
Grossly, GIST are typically well-circumscribed, highly vascular tumours, and may show areas 
of hemorrhagic necrosis and cystic degeneration. The tumour size is variable, from small 
tumours measuring a few millimetres to very large masses of several centimetres. 
Histologically, GIST display either a spindled (70%), epithelioid (20%) or mixed (10%) 
cytomorphology. Overall, GIST are characterized as uniform and monotonous tumours with 
variable cellularity. Sclerotic, collagenous, or myxoid stromal changes can be seen in each 
subtype [179]. 
Approximately 95% of GIST show CD117/KIT protein expression [180]. KIT immunostaining 
can appear in three distinctive patterns in GIST: a strong diffuse cytoplasmatic staining, a 
membranous staining, or a paranuclear dot-like staining, often referred to as “Golgi pattern” 
[18]. The first pattern is observed in the majority of the cases, often associated with dot-like 
staining. GIST carrying homozygous KIT or PDGFRA mutations can show a predominantly 
paranuclear dot-like KIT immunostaining. Even though KIT represents the most important 
marker for GIST diagnosis, KIT expression can be detected also in other cancer types such as 
melanomas, mast cell malignancies, germinomas, breast carcinomas and some leukemias. 
Moreover, about 5% of GIST are completely KIT immunonegative [180]. These cases are more 
likely to have epithelioid cell morphology and carry PDGFRA oncogenic mutations [29], 
although the presence of KIT mutations cannot be excluded [18]. To note, KIT-negative GIST 
might benefit from KIT-targeted therapy. The calcium-activated chloride channel 
TMEM16A/ANO1, known as DOG-1, has emerged as an alternative marker for the diagnosis 
of GIST. Around 97% of GIST are positive for DOG-1, including KIT-negative tumours [26, 
181]. The combination of CD117 and DOG-1 staining capture essentially all cases. These 
antigens are only rarely expressed in other mesenchymal tumours. Less sensitive and less 
specific GIST biomarkers are CD34 (70% of the cases), PDGFRA (80%), PKCƟ (80-90%), 
carbonic anhydrase II (95%), and h-caldesmon (85%) [18, 180]. In addition, loss of normal 
SDHB and SDHA expression can be detected by immunohistochemistry to identify SDH-
deficient GIST. 
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The clinical presentation of GIST is considerably variable and includes incidentally detected 
tumours and symptomatic cases. Generally, the symptoms are related to the size and anatomical 
localization of the tumour mass, which displaces adjacent structures rather than infiltrating 
them. The most common symptoms include abdominal pain, bloating, earlier satiety, and 
chronic gastrointestinal bleeding, which is causing anaemia. Some patients may present life-
threatening symptoms, such as intestinal obstruction, acute gastrointestinal bleeding due to 
ulceration of overlying mucosa or tumour rupture. Initial patient evaluation includes 
endoscopy, endoscopic ultrasound, and computed tomography scan, which show tumour 
anatomic details. Whereas PET can assess baseline metabolic activity, which is important for 
both diagnosis and therapy effectiveness. Biopsy is performed for histopathological 
examination, crucial for differential diagnosis. 
10. Risk assessment and prognostic factors for GIST 
The spectrum of GIST clinical behaviour is wide, ranging from small indolent tumours to 
highly aggressive cancers. According to the 2002 consensus guidelines, all GIST may have 
malignant potential [1]. Therefore, GIST cannot be classified as benign or malignant but they 
are rather stratified in categories that predict the risk of aggressive clinical behaviour. Tumour 
size (maximum tumour diameter in cm) and mitotic activity (per 50 high power fields) are the 
two prognostic parameters of the risk assessment system proposed by Fletcher and colleagues 
in 2002 (NIH criteria, 2002). This classification was further complemented with the addition 
of anatomic tumour location by Miettinen et al. (AFIP criteria 2006, NCCN criteria 2007), 
since gastric GIST generally show better outcome than tumours with non-gastric origins [18]. 
Lastly, tumour rupture before or during surgery has been identified as an important risk factor 
(Table 1) [182].  
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Table 1. Assessment of the risk of recurrence in GIST. 
The genotype is not included as a parameter in the risk assessment calculation; however, in 
general GIST harbouring PDGFRA mutations have a decreased malignant potential. Likewise, 
WT-GIST, often show favourable prognosis, even though they tend to present as multifocal 
lesions and develop lymph node metastases. Additional genetic parameters, as the number and 
the type of genomic losses and gains, assessed for example by array comparative genomic 
hybridization, might be helpful to improve prognostication. As a matter of fact, GIST 
harbouring a higher number of gross chromosomal aberrations are associated with a more 
aggressive clinical course, and aneuploidy is a negative prognostic factor in GIST. Moreover, 
cell cycle dysregulation caused by downregulation of p16, p21, p27, and RB1, and upregulation 
of CDK4/6, cyclin A and cyclin B1 have been observed in advanced GIST, and correlate with 
unfavourable prognosis [183-184]. Aberrant p53 immunostaining also correlates with a poor 
prognosis. Nevertheless, inactivating TP53 mutations are rare in GIST, which renders these 
tumours to be potentially sensitive to reactivation of p53 through inhibition of MDM2, which 
subsequently induces cell cycle arrest by upregulation of p21 or apoptosis [185]. In addition, 
amplifications of MDM2 and CCND1 (which encodes cyclin D1) genes, though infrequent in 
Miettinen 2006 Joensuu 2008 
Tumour 
Size (cm) 
Mitoses 
(per 
50HPFs) 
Gastric 
Small 
Bowel 
Tumour 
Size (cm) 
Mitoses 
(per 
50HPFs) 
Primary 
Tumour site 
Risk 
Assessment 
≤2 
<5 
Very low Very low ≤2 ≤5 Any Very low 
>2≤5 Very low Low >2≤5 ≤5 Any Low 
>5≤10 Low Intermediate >2≤5 >5 Gastric 
Intermediate >10 Intermediate High ≤5 6-10 Any 
≤2 
≥5 
Very low Intermediate >5≤10 ≤5 Gastric 
>2≤5 Intermediate High Any Any 
Tumour 
Rupture 
High 
>5≤10 High High >10 Any Any 
>10 High High Any >10 Any 
    >5 >5 Any 
    >2≤5 >5 Non-Gastric 
    >5≤10 ≤5 Non-Gastric 
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GIST, are associated with malignancy. Finally, Chibon and colleagues have proposed a 
prognostic gene expression signature, the “complexity index in sarcomas” (CINSARC), to 
predict clinical outcomes of patients affected by different kind of sarcoma as well as GIST 
[186]. The CINSARC signature includes 67 genes involved in maintenance of chromosome 
integrity and mitotic control. They have found that AURKA overexpression, a mitotic 
centrosomal protein kinase, induces centrosome duplication and segregation abnormalities 
leading to aneuploidy and subsequently malignant transformation. 
11. Therapeutic targets and mechanisms of resistance 
Surgery represents the standard treatment for localized resectable GIST (70-80% of patients). 
However, approximately 50% of patients that undergo tumour resection develop recurrences 
or metastases. As a matter of fact, rupture of the tumour capsule and surgical removal of high 
risk GIST are associated with increased postoperative recurrences [18, 187]. GIST are 
refractory to chemotherapy and radiotherapy [9, 188], and the prognosis for advanced GIST 
was poor before the advent of targeted therapies. In 2002 imatinib mesylate (STI571, Gleevec; 
Novartis Pharma, Basel, Switzerland) was introduced into the clinic. It is a TKi that presents 
inhibitory activity against ABL, ARG, CSF1R, LCK, PDGFRA/B and KIT [9,189]. More 
specifically, imatinib is a 2-phenylpyrimidine derivative, which mimics the structure of ATP 
molecules and it is able to competitively occupy the ATP-binding pocket of the target kinase 
(TK1 domain in KIT) by establishing non-covalent hydrogen bindings with specific amino 
acids [190]. Hence, imatinib prevents ATP hydrolysis and subsequently blocks the receptor 
kinase activity and the activation of downstream signalling pathways [8]. To note, imatinib 
displays higher affinity for the monomeric inactivate KIT isoform compared to the activated 
dimer [190]. As a matter of fact, imatinib inhibits KIT by stabilizing its inactivated 
conformation. Thus, imatinib efficacy depends on the equilibrium between activated and 
inactivated KIT. To date, imatinib represents the first line treatment approved for advanced 
(unresectable, metastatic or recurrent) GIST patients [179]. In addition, it can be administrated 
as adjuvant therapy after surgery to prevent recurrences, as well as neoadjuvant to downsize 
primary or metastatic tumours before surgery [191-193]. In general, standard dose of imatinib 
in GIST is 400 mg/day [194]. It is well tolerated and safe, and it is administrated orally and 
continuously until disease progression or drug intolerance. Notably, approximately 85% of 
GIST patients with advanced tumours show complete (5%) or partial response (50%) or 
achieve long-lasting stable disease (30%) [11, 12, 194]. Moreover, the median overall survival 
for these patients increased from 12-19 months to 3-5 years thanks to imatinib therapy [9, 13, 
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195]. Nevertheless, complete responses are rare and imatinib is considered as a non-curative 
therapy in advanced, metastatic GIST [12, 13, 196]. Eventually, the majority of cases develop 
resistance to this drug [13, 197].  
In approximately 10-15% of GIST patients, tumour progression is observed within 6 months 
of treatment; this is referred to as primary resistance. Notably, clinical responses are quite 
heterogeneous and they are highly related to the tumour genotype. Primary resistance to 
imatinib occurs in patients with KIT exon 11 and KIT exon 9 mutants, and WT-GIST in 5%, 
16%, and 23%, respectively [80, 83, 195, 196, 198, 199 ], and inevitably in PDGFRA-D842V 
mutants [91, 200]. On the other hand, the majority of GIST patients that initially benefit from 
imatinib treatment, eventually experience disease progression; referred to as secondary 
resistance. Development of secondary resistance is mainly due to the acquisition/selection of 
new non-random KIT/PDGFRA mutations (67%-80% of cases) [19, 82, 201-203], and more 
rarely to genomic amplification of KIT, with subsequent kinase overexpression, or activation 
of an alternative pathway often associated with loss of KIT oncoprotein expression [28, 82, 
204]. Interestingly, secondary KIT or PDGFRA resistance mutations normally arise in the same 
gene and allele as the primary oncogenic driver mutation [79, 205] and affect either the ATP 
binding pocket (TK1 domain) or the kinase activation loop (TK2 domain) of the receptors 
[197]. In the first case, the mutation directly disrupts the binding site of imatinib, by replacing 
those amino acids that are involved in the hydrogen bonds with the drug [197]. In the second 
case, the mutation stabilizes the receptor into a hyper-activated conformation which is no 
longer sensitive to the drug. Secondary mutations occur mostly in primary KIT exon 11 mutant 
GIST, less frequently in KIT exon 9 mutants, whereas they are not observed in WT-GIST [203]. 
Notably, several secondary resistance mutations can be found among different metastatic 
lesions or even within the same lesion of a single GIST patient [81]. The tumour mass is 
composed of clones harbouring different mutations, and during TKi treatment the clones 
resistant to that particular drug are selected and can expand leading to disease progression [95]. 
Thus, the substantial heterogeneity present in an individual patient can significantly affect the 
efficacy of TKi therapy, as it can preclude the systemic eradication of all GIST cells. Moreover, 
the selective pressure under TKi treatment could also lead to the selection of clones that present 
phenotypic changes, such as a shift to a more epithelioid morphology, expression of skeletal 
muscle marker (desmin and myogenin), and lack of KIT expression at the protein level [32, 
82]. This suggests that mechanisms of resistance independent of KIT occur in GIST patients, 
and that an alternative oncogenic mechanism is driving the neoplastic proliferation. Finally, 
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one more reason of imatinib treatment failure in GIST patients may be due to inadequate 
exposure of the tumour tissue to the drug. Imatinib pharmacokinetics differs between patients 
and part of them show decreased imatinib plasma levels over time. This might be due to 
decreased imatinib intestinal absorption, erythrocyte-dependent sequestration of the drug, or 
cytochrome P450-dependent alteration of imatinib metabolism [206].  
Even though the majority of GIST patients eventually progress under imatinib therapy, in most 
of the cases these tumours are still dependent on KIT activation [207]. In this circumstance, 
other KIT-related strategies might be applied to overcome the problem of resistance.  
One first approach used in the clinic is imatinib dose escalation up to 800 mg/day. GIST 
patients which harbour KIT exon 9 mutations benefit from higher doses of imatinib, as well as 
GIST carrying gain of KIT copy numbers and WT-GIST, as demonstrated by in vitro 
experiments [29, 178, 198, 208]. Moreover, in some patients, increased imatinib dose might 
help to maintain constantly an ideal plasma or intracellular concentration level of the drug [206, 
209]. 
Another strategy for the treatment of imatinib-resistant GIST is the administration of 
alternative kinase inhibitors with better binding affinity and pharmacologic profile, and able to 
inhibit different KIT secondary mutations [201, 210-212]. Several new TKi are being explored 
like sunitinib, nilotinib, dasatinib, sorafenib, regorafenib, ponatinib, masatinib, mosetanib, 
vatalanib and crenolanib. Some of them are multi-target drugs and they have the ability to 
synergistically inhibit other signalling, i.e. anti-angiogenesis, and downstream factors [197, 
213]. Sunitinib is a multi-tyrosine kinase inhibitor FDA-approved second line treatment for 
GIST patients not-responsive or intolerant to imatinib. It inhibits KIT, PDGFRA/B, 
VEGFR1/2/3, FLT3 and ret proto-oncogene [214]. In particular, sunitinib is effective against 
imatinib-resistant secondary mutations located in the ATP binding pocket (TK1 domain) [197]. 
Moreover, KIT exon 9 mutants and WT-GIST showed high sensitivity to this drug [198]. For 
the latter, good responses are probably due to inhibition of VEGFR signalling. However, 
sunitinib is not able to inhibit secondary mutations in the activation loop (TK2 domain) and 
patients that benefit from the treatment eventually progress. Recently, regorafenib has been 
approved by the FDA as third-line treatment for imatinib and sunitinib resistant GIST patients. 
Regorafenib is a fluoride derivative of sorafenib, and it is effective against secondary resistance 
mutations in the activation loop (TK2 domain). However, also for this drug, cross-resistances 
develop over time. All in all, none of these drugs is effective against all the secondary resistance 
mutations that arise during GIST tumours progression. Hence, novel strategies need to be 
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investigated to overcome heterogeneity in GIST patients. One option would be combination 
therapies, considering the limits of toxicity and secondary effects. For instance, an approach to 
suppress a broader spectrum of drug-resistant GIST subclones has been proposed recently by 
Serrano and colleagues [215]. It consists in a sequential rapid-alternation regimen of sunitinib 
for 3 days followed by regorafenib for 4 days. Cycling these two drugs might lead to prolonged 
long-term disease control minimizing toxic effects.  
Other approaches that still have KIT inhibition as a goal are the use of monoclonal antibodies 
against the ligand-binding domain of KIT receptor [197] or of genetically modified or designer 
anti-KIT T-cells (dTc) to target KIT-positive GIST, which induces GIST cell lysis [216]. 
Additionally, a new class of switch pocket kinase inhibitors is now available. These molecules 
are able to stabilize the inactive form of KIT regardless of the activated or inactivated 
conformation of the receptor [211]. Finally, transcriptional repression of KIT mRNA in GIST 
cells can be achieved by treatment with flavopiridol or quadruplex-binding small molecules 
[217-218]. However, all these strategies are still under investigation.  
As previously described, GIST cells growth, proliferation and survival strongly depend on the 
activation of RAS/RAF/MAPK and PI3K/AKT/mTOR pathways, downstream of KIT 
receptor, regardless of the tumour genotype [44]. Therefore, another possible strategy to 
overcome the problem of resistances to TKi therapy, due to extensive molecular heterogeneity 
of GIST tumours, is to target crucial KIT-depending signalling intermediates. In vitro 
experiment carried by Bauer and colleagues showed that, despite the importance of MAPK 
pathway activation in GIST, targeted inhibition of MEK1/MEK2 did not reduce cell 
proliferation and did not induce apoptosis [207]. Nevertheless, NF1-related and BRAF-mutants 
GIST might benefit from the inhibition of the RAS/RAF/MAPK pathway. On the other hand, 
PI3K inhibition resulted in a more marked effect on cellular proliferation and apoptosis in 
various GIST cell lines [207]. These findings suggest that the PI3K/AKT/mTOR pathway 
might be more suitable as therapeutic target in GIST tumours. Several PI3K, AKT or mTOR 
inhibitors have been recently developed and are being tested in preclinical and clinical trials. 
The mTOR inhibitor everolimus (RAD001, Novartis Pharmaceuticals) combined with imatinib 
showed only minor anti-proliferative effects and no proapoptotic activity in GIST cell lines 
[207]. Modest results have been obtained, with the same treatment, in phase I-II clinical trials 
for patients with imatinib resistant GIST [219]. Limited efficacy of mTOR inhibition might be 
due to re-activation of the upstream PI3K/AKT pathway by the release of negative 
mTORC1/S6K/IRS1 feedback loop [207, 220, 221]. Several novel compounds able to inhibit 
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all PI3K subunits and mTORC1/2, at variable degrees, have been developed [222]. GDC-0941 
(Genentech) is a potent and selective pan-inhibitor of class I PI3K able to target also PI3K 
p110a subunit mutant forms, whereas it is a weak inhibitor of mTOR. Preclinical in vivo studies 
performed on GIST xenografts showed that GDC-0941 alone displayed only minimal activity 
on cancer cell proliferation and apoptosis, and on tumour volume. On the contrary, GDC-0941 
in combination with imatinib effectively decreased proliferation and induced cell death, with 
long-lasting effects after treatment withdrawal [223]. Similar results were obtained in a recent 
study where other PI3K inhibitors (PI3Ki) (namely BEZ235, BYL719 and BKM120; all from 
Novartis) have been tested on GIST xenograft models [224]. Overall, the efficacy of PI3Ki 
used as a single agent for the treatment of GIST might be reduced due to the complexity of the 
signalling, characterized by the presence of cross-talks and negative feedback loops at different 
levels, as previously described. A more powerful approach would be PI3Ki/TKi combination 
therapy. Currently, several clinical trials are on-going to test the efficacy of TKi and PI3Ki 
combination treatment [http://www.clinicaltrials.gov: NCT01468688, NCT01735968]. 
Ideally, a dual inhibition of both PI3K/AKT and RAS/MAPK pathways could represent the 
best strategy. Research efforts are moving to that direction. However, toxicity concerns of such 
combination should be solved to be considered as a realistic option in the clinic. Finally, the 
AKT inhibitor perifosine, able to prevent the translocation of Akt to the cell membrane, in 
combination with imatinib has been tested in a phase 2 study for the treatment of imatinib-
resistant GIST. It showed good efficacy in a small group of WT-GIST patients, but overall only 
limited clinical activity [225]. 
Even though KIT and PDGFRA are the main driving force of most GIST, KIT/PDGFRA-
independent strategies, where the primary target is not represented by the receptors themselves, 
might be effective to overcome TKi resistance. For instance, the chaperon heat shock protein 
90 (HSP90) is necessary for the correct folding, localization and stabilization of the 
KIT/PDGFRA oncoproteins. It is has been demonstrated both in vitro and in vivo that targeting 
HSP90 leads to KIT degradation, and consequently arrest of proliferation and induction of 
apoptosis, independently of the type of oncogenic mutations [226-228]. However, clinical 
translation of HSP90 inhibition in GIST resulted in low response rate and high toxicity, 
probably due to its vast number of client proteins. Recently, Mariño-Enriquez and colleagues 
have identified, through genome wide functional screening, the kinase-specific co-chaperone 
CDC37 as an alternative target for HSP90 complex inhibition. Preclinical studies have shown 
effective down-regulation of KIT expression and selectivity for only a subset of HSP90 client 
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proteins, which could reduce toxicity effects [229]. Another target is represented by histone 
deacetylase (HDAC), which is able to repress KIT mRNA transcription as well as HSP90 
activity, resulting in the inhibition of the oncogenic signalling, and significant induction of 
apoptosis. HDAC inhibitors alone or in combination with imatinib might represent a valid 
treatment options in KIT-positive GIST [230-231]. Lastly, the inhibition of the proteasome 
complex by bortezomib resulted in KIT degradation and downstream signalling inhibition and 
subsequent cell death in GIST cell lines harbouring various resistance mutations and in 
transgenic mice [232] 
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AIMS 
1. Promoting role of cholecystokinin 2 receptor (CCK2R) in gastrointestinal stromal 
tumours pathogenesis 
CCK2R has been shown to have growth-promoting effects on pre-neoplastic gastrointestinal 
cells when stimulated by gastrin. CCK2R is highly expressed in GIST. We sought to investigate 
the incidence and functional significance of CCK2R and CCK2Ri4sv in GIST pathogenesis. 
To this aim, we performed inclusive molecular characterization of CCK2R and CCK2Ri4sv in 
a broad collection of heterogeneous type of GIST, and explored the hypothesis that CCK2R 
contributes to GIST growth through in vivo studies using GIST xenografts. 
 
2. Frequent mono-allelic loss associated with deficient PTEN expression in imatinib 
resistant gastrointestinal stromal tumours 
In many human cancers PTEN deficiency is associated with advanced tumour stage and is 
related to resistance to TKi. The PI3K/AKT/mTOR signalling pathway represents a crucial 
driving force for the growth, survival and progression of GIST. In this study, we have 
performed a comprehensive molecular and immunohistochemical characterization of PTEN in 
a heterogeneous cohort of GIST, including imatinib-resistant tumours, to assess the incidence 
and the nature of PTEN malfunction during GIST progression and during the course of imatinib 
therapy. Furthermore, we have investigated the impact of small interfering RNA (siRNA) 
PTEN knock-down on KIT signalling in imatinib-sensitive and imatinib-resistant GIST cell 
lines treated with a dual PI3K/mTOR inhibitor alone or in combination with imatinib, in order 
to better understand the functional consequences of PTEN insufficiency in GIST cells. 
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RESULTS 
1. Promoting role of cholecystokinin 2 receptor (CCK2R) in gastrointestinal stromal 
tumours pathogenesis 
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resistant gastrointestinal stromal tumours 
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Abstract 
The cholecystokinin 2 receptor (CCK2R/CCKBR) is expressed in gastrointestinal stromal 
tumours (GISTs). We sought to investigate the role of CCK2R in GIST pathogenesis. 
Molecular characterization of CCK2R was performed on a heterogeneous cohort of 50 GISTs. 
In addition, CCK2R expression was evaluated by immunohistochemistry (IHC), using tissue 
microarray (TMA) containing 292 GISTs, two cases of hyperplasia of interstitial Cajal’s cells 
(ICC) and six gastric microscopic GISTs. Mono-allelic loss of the CCK2R/11p15 allele was 
identified in 13.7% of GISTs, having no impact on the level of CCK2R transcript expression. 
No CCK2R mutations were found. The CCK2Ri4sv, CCK2R splice variant with retention of 
intron 4 was detected in six of 20 tumours analysed. Wild-type CCK2R transcripts were 
commonly expressed (57.1% of cases) and this expression was highly correlated with gastric 
primary site of GISTs (p < 0.001). At the protein level, expression of CCK2R in incidental ICC 
hyperplasia and early stages of gastric GIST development was documented, and its gastric 
association was confirmed on GIST-TMA by IHC. To explore the in vivo effect of CCK2R 
activation on tumour growth, gastrin versus placebo was administered intraperitoneally in nude 
mice carrying human GIST xenografts. The tumour volume was followed for 10 weeks. The 
effect of this stimulation on tumour cell proliferation/apoptosis was assessed by IHC and 
KIT/PKC-θ signalling was evaluated by western blotting (WB). In vivo experiments showed a 
two-fold increase in the volume of tumours which were exposed to gastrin in comparison with 
non-exposed controls (p = 0.03), with a significant increase in mitotic activity (p = 0.04) and 
Ki-67 proliferation index (p = 0.008). By WB, gastrin stimulation resulted in hyper-activation 
of KIT and PKC-θ kinases, and in evident PI3K-AKT pathway over-activation. Our results 
indicate a promoting role of CCK2R on GIST tumourigenesis, particularly in tumours of gastric 
origin.  
Keywords: gastrointestinal stromal tumours; gastrin; CCK2R; micro-GIST; PKC-θ; stomach 
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Introduction 
Gastrointestinal stromal tumours (GISTs) are clinically and histologically heterogeneous 
neoplasms that exhibit interstitial cells of Cajal (ICC) differentiation [1, 2]. They occur 
predominantly in the stomach (50–60%) and small intestine (10–20%). The majority of GISTs 
are driven by oncogenic KIT or PDGFRA mutations, which are crucial therapeutic targets [3–
5]. GISTs have been estimated to occur with a frequency of 13.6/ million inhabitants [6], but 
minimal incidental GISTs (< 1 cm in size; micro-GISTs) are far more common (in 20–30% of 
elderly individuals) [7–9]. Based on these statistics, micro-GISTs likely represent preneoplastic 
lesions that might require additional genetic events or promoting external stimuli for evolution 
[7–11]. Cytogenetic and molecular studies have revealed compelling correlations between the 
biological progression of GISTs and chromosomal/ genomic alterations [12, 13]. Whether the 
specific microenvironment related to a particular anatomical site of origin plays a role in GIST 
development remains unclear.  
Of particular interest in relation to GISTs is the fact that specific receptors, such as 
cholecystokinin 2/gastrin (CCK2R), bombesin subtype 2 or neurotensin 1 (NTSR1), are 
frequently expressed in GISTs, emerging as potential targets for cancer therapy [14–18]. 
CCK2R, formerly named CCKB/gastrin receptor, belongs to the superfamily of the 7-
transmembrane α-helical domain G-protein-coupled receptors. The CCK2R is widely 
expressed in the central nervous system, where cholecystokinin is its endogenous ligand. At 
the periphery, it is located on parietal and enterochromaffin-like (ECL) cells within the gastric 
epithelium, where it mediates the action of gastrin [19, 20]. CCK2R has been shown to have 
growth-promoting effects on preneoplastic gastrointestinal cells when stimulated by gastrin 
[21–25]. Gastrin-dependent activation of the CCK2R may activate important effectors 
involved in proliferation and survival, such as protein kinase C (PKC) and protein kinase B 
(PKB/AKT), throughout the direct interaction [26–30]. Interestingly, CCK2R has been 
described to be well expressed in many neoplasms of different origin (eg neuroendocrine 
tumours and adenocarcinomas), while not being present in the corresponding normal tissues, 
indicating an important role in carcinogenesis [19, 31].  
Human gastrointestinal (GI) tract cancers express at least three variants of CCK2R: (a) 
CCK2R, the original variant identified as the receptor mediating normal gastric acid secretion 
and ECL proliferation; (b) an N-terminal truncated form of CCK2R (ΔCCK2R); and (c) 
CCK2Ri4sv, which encodes an isoform containing an additional 69 amino acid residues in its 
third intracellular loop domain [32–34]. Importantly, CCK2Ri4sv is reported to exhibit 
Results | Role of gastrin receptor in GIST development 
 
- 48 - 
 
agonist-independent activation of the proto-oncogene SRC in pancreatic cancer [35] and 
constitutive activation of PKB/AKT in an oesophageal cancer cell line [30]. Although the 
expression of CCK2R in GISTs is well recognized, the incidence and functional significance 
of these receptors in GISTs were not investigated. Given the potential clinical importance, we 
performed molecular characterization of CCK2R in a broad collection of heterogeneous types 
of GIST and explored the hypothesis that the CCK2R receptor contributes to GISTs growth. 
Materials and methods 
Patients and samples 
This study was approved by the Ethical Committee of KU Leuven (ML7481). Frozen samples 
from 50 resected imatinib-naïve GISTs, originating from 49 patients (17 female and 32 male, 
aged 33–83 years), were selected from the files of the Department of Pathology, KU Leuven. 
These were heterogeneous tumours with regard to primary anatomical site, KIT/PDGFRA 
genotype and histopathological grade (35 primary and 15 malignant GISTs). Tumour risk 
assessment was performed using AFIP criteria [1] (Table 1).  
In addition, two cases of ICC hyperplasia, found in colon and small intestine in male patients 
with diverticular disease, were studied, as well as six cases of gastric micro-GISTs 
coincidentally found in patients (four male and two female, aged 55–76 years) with gastric 
carcinoma. Histopathological examination was performed on formalin-fixed, paraffin-
embedded (FFPE) tissue; 4 μm sections were used for routine haematoxylin and eosin (H&E) 
staining. Immunohistochemistry (IHC) was performed using antibodies against CD117 
(dilution 1 : 250; Dako), CD34 (1 : 10; Becton-Dickinson), CCK2R (1 : 300; EB06767, Everest 
Biotech) and gastrin (1 : 200; Thermo Scientific). The Envision+ System HRP-labelled polymer 
(Dako) was used for the development of the staining. 
Fluorescence in situ hybridization (FISH) 
Genomic copy number changes were investigated by FISH on FFPE tumour sections by co-
hybridization of spectrum orange-labelled, bacterial artificial chromosome DNA RP11-98L18 
(specific for CCK2R/11p15.4) and spectrum green-labelled chromosome 11 centromeric 
(CEP11; Abbott Laboratories) probes. Probe labelling, hybridization and criteria for evaluation 
were carried out as described previously [36].  
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Mutational analysis  
DNA was isolated and KIT /PDGFRA mutations were assessed as reported [37]. CCK2R exons 
1–5 were amplified by polymerase chain reaction (PCR), using standard Taq DNA polymerase 
(Roche), and sequenced bidirectionally, using ABI PRISM 2700 (Applied Biosystems). The 
specific primers for amplified fragments were designed using Primer3 software 
(Supplementary Table S1). 
Quantitative reverse transcription PCR (qRT–PCR) 
RNA was isolated from frozen tissues using an RNeasy Mini Kit (Qiagen), including a DNase 
I digestion step. Reverse transcription was performed using SuperScript III (Invitrogen).  
For qRT–PCR, two different reactions were carried out to amplify either total CCK2R or 
CCK2Ri4sv cDNA. The cDNA corresponding to 100 ng total RNA was amplified in a 15 μl 
reaction volume, using qPCR MasterMixPlus for SYBR® Green I without UNG (Eurogentec) 
in a Light Cycler 480 (Roche). For normalization, the endogenous reference genes GUSB and 
HPRT were used. As positive and negative controls, the previously described [38,39] human 
oesophageal squamous carcinoma cell lines stably expressing or not expressing wild-type 
CCK2R (OE33GR+ versus OE33 cells), a kind gift from Dr Jankowski (University of 
Liverpool, UK), were used. Two sporadic leiomyosarcomas and normal brain, stomach and 
liver were also studied. Primers for the genes analysed were designed using Light Cycler Probe 
Design2 (Roche) (Supplementary Table S1).  
For statistical analysis, the Mann–Whitney U-test was performed, using the software package 
Statistica (StatSoft Inc., USA). 
End-point PCR 
In 20 GISTs positive for CCK2R expression, possible CCK2R transcript variants were 
investigated by a nested PCR, in which the first-round reaction amplified total CCK2R cDNA 
and the second-round reaction either wild-type (WT) CCK2R or CCK2Ri4sv, as described [32]. 
Normal brain and liver tissues were also investigated. Amplicons were sequenced to confirm 
their identities, using bidirectional Sanger sequencing. The end-point PCR protocol is 
presented in Supplementary methods. The primers design is shown in Figure 2B and their 
sequences are presented in Supplementary Table S1. 
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CCK2R/gastrin expression by IHC 
The expression of gastrin and CCK2R at the protein level was investigated by IHC, using 
GIST-TMA containing a heterogeneous set of 292 FFPE tumours, micro-GISTs, and on cases 
of ICC hyperplasia (detailed in Supplementary Table S2). Normal stomach specimens were 
included in the study as positive controls. The protocol for CCK2R/gastrin immunostaining is 
presented in Supplementary methods. Staining was regarded as positive when specific (ie 
above background) CCK2R/gastrin immunostaining signal was present in > 10% of tumour 
cells. 
For statistical analysis, TMA data were fitted using a multivariate logistic regression model 
with the binary variable CCK2R protein expression (0/1 or negative/ positive) as a response 
variable. The patient gender, tumour site, histology grade and KIT/PDGFRA genotype were 
used as explanatory variables. The analysis was performed using SAS software, v 9.2, of the 
SAS System for Windows.  
In vivo study 
Nude mice (adult female NMRInu/nu, n = 8) were grafted bilaterally with recurrent gastric GISTs 
(carrier of KIT-V560D mutation), in which CCK2R expression was confirmed by quantitative 
and nested RT–PCR. The animals were randomized into two groups and injected 
intraperitoneally with either vehicle only (0.9% NaCl, group 1) or the CCK2R agonist gastrin 
(Sigma-Aldrich), at 10 ng/kg every third day (group 2). Tumour volume was assessed using 
vernier callipers every second day, as described [40]. After 10 weeks of treatment, the mice 
were sacrificed and xenograft tissues were partially preserved in formalin or snapfrozen for 
further evaluation.  
Tumour proliferation indices were assessed by routine H&E and Ki-67 staining, as described 
[40]. In short, mitoses were counted in 10 high power fields (HPFs) at 400-fold magnification 
on H&E slides. For Ki-67 proliferative index, IHC was performed using anti-Ki-67 monoclonal 
rabbit clone SP6 antibody (1 : 200; Thermo Scientific). Ki-67 index was determined by 
evaluating the average percentage of positive nuclei in three HPFs. Statistics were performed 
using Mann–Whitney U-test (Statistica software v 9.0).  
KIT–PKC-θ signalling was evaluated by western blotting (WB), as reported [37], using 
antibodies against total KIT (Dako), total MAPK (Zymed Laboratories), total PKC-θ (Santa 
Cruz Biotechnology), phospho-KIT, phospho-PKC-θ, phospho-AKT (Ser473), total AKT, 
phospho-MAPK, phospho-S6, total S6 and cleaved caspase-3 (Cell Signaling). An antibody 
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against B-actin (Sigma-Aldrich) was applied as a protein-loading control. The HRP-conjugated 
anti-rabbit or anti-mouse IgG (Dako) was used as a secondary reagent and proteins were 
visualized with Enhanced Chemiluminescence (Thermo Scientific), which was captured with 
the FUJI mini-LAS4000 imaging system. Densitometry analysis was performed using AIDA 
software (Raytest). The optical density of each band was measured and normalized against B-
actin. 
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Table 1. The clinico-pathological and molecular data of 50 GIST retrieved for the study 
No. 
Age 
[years] 
Sex 
Primary 
site 
Histotype 
Size 
[mm] 
MI  
[per 
50 
HPF] 
IHC Risk of 
primary*/ 
 overtly 
malignant 
KIT/PDGFRA 
exon mutation 
CCK2R 
loss by 
FISH 
CCK2R expression 
CD117 CD34 
qRT-
PCR 
CCK2Ri4sv** IHC 
1 75 M stomach epith. 30 3 pos pos v. low PDGFRA 14 no pos neg pos 
2 66 F stomach mixed 35 4 pos pos v. low PDGFRA 18 no neg nd nd 
3 77 F stomach epith. 60 4 pos pos low PDGFRA 12 no neg nd nd 
4 55 M stomach mixed 50 5 pos pos low PDGFRA 14 no neg nd nd 
5 71 M stomach epith. 55 1 pos pos low PDGFRA 18 no pos neg nd 
6 49 M stomach epith. 75 4 neg pos low PDGFRA 18 no neg nd nd 
7 69 M stomach spindle 35 4 pos pos low PDGFRA 18 no pos neg nd 
8 76 F stomach epith. 30 17 pos pos intermed. PDGFRA 18 no pos pos pos 
9 53 M stomach mixed 55 4 pos pos intermed. PDGFRA 18 no pos pos pos 
10 51 M stomach spindle 180 2 pos pos high PDGFRA 18 no pos nd pos 
11 61 M stomach spindle 55 5 pos pos low KIT 11 no pos pos pos 
12 53 M stomach epith. 6 5 pos neg low KIT 11 no pos nd pos 
13 64 M stomach spindle 45 9 pos pos low KIT 11 no pos nd pos 
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14 83 M stomach spindle 50 4 pos pos low KIT 11 no pos pos nd 
15 80 F stomach spindle 55 3 pos pos low KIT 11 no pos nd nd 
16 36 F stomach spindle 35 60 pos pos intermed. KIT 11 no pos neg neg 
17 67 F stomach spindle 40 25 pos pos intermed. KIT 11 no pos pos nd 
18 83 F stomach spindle 85 7 pos pos intermed. KIT 11 no pos pos nd 
19 56 M stomach spindle 45 15 pos pos intermed. KIT 11 no pos nd nd 
20 48 F stomach spindle 50 37 pos neg high KIT 11 no pos neg pos 
21 67 M stomach mixed NA 22 pos pos high KIT 11 no neg nd nd 
22 49 M stomach spindle 80 26 pos pos high KIT 11 no pos nd nd 
23 57 M stomach spindle 140 14 pos neg high KIT 11 no pos neg nd 
24 43 M stomach mixed 8 15 pos neg M (meta) KIT 11 yes neg nd nd 
25 74 M stomach spindle 110 30 pos pos M (rec) KIT 11 no pos nd pos 
26 72 M sm. int. spindle 48 4 pos pos low KIT 11 no pos neg pos 
27 37 F sm. int. spindle 120 1 pos neg high KIT 11 no pos neg nd 
28 51 M sm. int. spindle 120 15 pos neg high KIT 11 yes pos nd pos 
29 78 M sm. int. spindle 55 12 pos neg high KIT 11 no neg nd neg 
30 51 M sm. int. spindle 150 8 pos neg high KIT 11 no neg nd neg 
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31a 
49 F 
sm. int. spindle 90 8 pos neg high KIT 11 no neg nd neg 
31b sm. int. spindle 70 12 pos neg M (rec) KIT 11 no neg nd neg 
32 78 M sm. int. spindle 280 5 pos pos M (rec) KIT 11 no pos neg neg 
33 59 M sm. int. epith. NA 38 pos pos M (rec) KIT 11 yes neg nd nd 
34 59 F sm. int. spindle 100 52 pos pos M (meta) KIT 11 no pos nd pos 
35 45 M sm. int. spindle 90 40 pos neg M (meta) KIT 11 no neg nd nd 
36 45 M sm. int. spindle 30 20 pos neg M (rec) KIT 11 no neg nd neg 
37 50 M sm. int. spindle 70 10 pos neg M (meta) KIT 11 yes neg nd neg 
38 68 F duod. spindle 30 4 pos pos intermed. KIT 11 no pos neg nd 
39 65 M rectum spindle 55 26 pos pos M (meta) KIT 11 no neg nd nd 
40 54 F sm. int. spindle 65 13 pos neg high KIT 9 no neg nd nd 
41 61 M sm. int. mixed 38 7 pos pos high KIT 9 no neg nd nd 
42 76 M sm. int. spindle 85 55 pos neg M (meta) KIT 9 yes neg nd nd 
43 44 M perit. spindle 180 25 pos pos M (meta) KIT 9 no pos neg nd 
44 50 F sm. int. mixed 50 5 pos neg intermed. KIT 9 no neg nd neg 
45 58 M colon spindle 110 17 pos neg M (meta) KIT 9 yes neg nd neg 
46 61 M sm. int. epith. 80 5 pos pos high KIT 17 no neg nd neg 
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47 50 F stomach epith. 45 18 pos pos M (rec) WT no pos nd pos 
48 56 F stomach spindle 95 10 pos neg M (meta) WT no neg nd neg 
49 33 F stomach mixed multiple 46 pos pos high WT yes pos neg pos 
* According to AIFP classification; ** End-point analysis        
Abbreviations: F-female; M-male; sm. int.-small intestine; duod.-duodenum; perit.-peritoneum; epith.-epithelioid; NA-not available; MI-mitotic index; 
HPF-high power field; IHC-immunohistochemistry; pos-positive; neg-negative; v. low-very low; interm.-intermediate; M-overtly malignant; meta-
metastasis; rec-recurrent disease; WT-without detectable KIT/PDGFRA mutations; nd-not done 
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Results 
Histopathology 
On histology, the tumours showed a spindle, epithelioid or mixed histotype, typical of GIST. 
By IHC, the vast majority (98%) were KIT/CD117-immunopositive. CD34 positivity was 
found in 62.7% of tumours and predominantly in GISTs of gastric origin (p = 0.001; χ2 test) 
(Table 1).  
Two cases of sporadic ICC hyperplasia presented a focal proliferation of CD117/CD34 
immunopositive cells (size 3–5 mm) within the inner layer of the muscularis propria. In both 
cases mutation analysis revealed wild-type KIT /PDGFRA genotype.  
All micro-GISTs [size 3–15 (mean 9) mm] originated from gastric atrium or fundus. Histology 
revealed uniform spindle-cell morphology with low (0–3/50 HPFs) mitotic activity. All were 
KIT/CD34 immunopositive. Two cases revealed mutations in KIT exon 11 (p.W557_K558del 
and p.W557R, respectively).  
Molecular characterization and clinicopathological correlations of CCK2R expression in 
GIST  
By FISH, we investigated the genomic copy number changes of the CCK2R gene, which maps 
to chromosome 11p15.4; this region is frequently lost during malignant progression of GISTs 
(Figure 1). Mono-allelic loss of the CCK2R/11p15 allele was identified in 13.7% of the 
specimens (Table 1). Notably, this loss did not have significant impact on the level of CCK2R 
transcripts evaluated by qRT–PCR (p = 0.2). By direct sequencing, no mutations were 
identified in CCK2R in any of the examined cases.  
 
Figure 1. Dual-colour interphase FISH analysis on GIST specimen by co-hybridization of spectrum orange-
labelled CCK2R/11p15 (RP11-98L18) DNA (red signals) and spectrum green-labelled chromosome 11 CEP 
(green signals) probes. Mono-allelic CCK2R loss is evidenced by a single red hybridization signal in reference to 
two green signals in each of the tumour nuclei. 
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With regard to CCK2Ri4sv transcripts, expression levels were close to the detection limit of 
qRT–PCR. However, the end-point PCR analysis revealed the presence of CCK2Ri4sv in six 
of 20 GISTs analysed (Figure 2A). Of note, all CCK2Ri4sv-positive tumours were of gastric 
origin and of low malignancy potential.  
 
Figure 2. Nested PCR. (A) Agarose gels showing representative end-point RT–PCR products: (a) second-round 
nested PCR products for CCK2R WT; (b) second-round nested PCR products for CCK2Ri4sv; (c) B-actin control 
PCR, run for each sample. All GIST samples analysed expressed CCK2R, included GIST xenografts used for the 
in vivo study. CCK2R transcripts were present in normal brain tissue but not in normal liver. CCK2Ri4sv 
transcripts were detected only in six GIST cases. For the negative control, no template was added. 1 kb DNA 
ladder was used as molecular weight marker. Additional bands migrating with higher weights correspond to 
amplified genomic CCK2R or are non-specific, as confirmed by sequencing. (B) Primer design for nested PCR. 
Splice variant mRNA was not identified in the normal tissues. The presence of CCK2Ri4sv 
transcript was confirmed by sequencing. By qRT–PCR, CCK2R transcripts were commonly 
expressed from low-risk to overtly malignant GISTs (57.1% of tumours). This expression was 
highly correlated with gastric primary site (gastric 75% versus non-gastric 32%; p < 0.001), 
irrespective of the KIT/PDGFRA genotype. In addition, the level of CCK2R transcript 
expression was eight-fold higher in tumours of gastric origin when compared to GISTs of non-
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gastric origin (p = 0.001). The low/intermediate-risk GISTs expressed CCK2R more frequently 
than high-risk/overtly malignant tumours (74.8% versus 41.4%, respectively; p = 0.01) (Table 
1). Stomach and whole brain were positive for the total CCK2R transcripts, whereas liver and 
the leiomyosarcomas were negative. 
CCK2R expression was also explored on the previously published normalized gene expression 
data of a cohort of 62 primary GISTs [13], using t -test. This analysis confirmed that CCK2R 
is under-expressed in intestinal versus gastric GISTs (log fold change intestinal versus gastric 
= −3.2) and lower in high versus low/intermediate-risk tumours (log fold change 
low/intermediate- versus high-risk = 2.8).  
IHC analysis 
The results of CCK2R expression frequency and clinicopathological correlations at the protein 
level were validated and confirmed by IHC, using GIST-TMA. CCK2R immunopositivity was 
disclosed in 60.9% of the specimens, with either a cytoplasmic or mixed (ie cytoplasmic and 
nuclear) immunostaining pattern (Figure 3C, D). The nuclear localization is believed to be due 
to a rapid internalization and translocation of the receptor to the nucleus, of still unknown 
functional significance [41]. Negative CCK2R immunostaining was found in adjacent non-
tumoural tissues and controls (Supplementary Figure S1). By univariate analysis, gastric 
primary location, presence of KIT exon 11 mutation and low/intermediate malignancy risk 
correlated significantly with CCK2R immunopositivity. However, in multivariate analysis, 
only gastric site of origin remained highly statistically significant [p < 0.0001; OR 4.6 (2.3–
9.1), 95% CI] (Supplementary Table S2).  
By IHC, both cases of focal ICC hyperplasia showed CCK2R immunopositivity (Figure 3E, 
F). Also, all gastric micro-GISTs showed clear CCK2R protein expression, albeit with varying 
levels of staining intensity (Figure 3G, H).  
Negative gastrin immunostaining was observed in all cases on GIST-TMA. Similarly, negative 
results were obtained in cases of ICC hyperplasia and micro-GIST, although positive gastrin 
immunostaining was detected in G cells of gastric mucosa specimens that were used as positive 
controls (Supplementary Figure S2). 
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Figure 3. Representative examples of histological and immunohistochemical images on FFPE GIST and control 
tissues. (A) Normal stomach (control): parietal cells within gastric mucosa stain positive for CCK2R (×20). (B) 
CCK2R immunonegative GIST (×200). (C) Gastric GIST showing cytoplasmatic pattern of CCK2R 
immunostaining; *adjacent non-tumoural tissue exhibited only minimal background signal (×200; insert ×400). 
(D) CCK2R immunopositive GIST; cytoplasmic and nuclear (mixed) pattern of staining (×200). (E) Incidental 
ICC hyperplasia in the colon, H&E (×20); (lower insert) H&E (×400); (upper insert) KIT immunopositive 
hyperplastic ICC cells (×400). (F) CCK2R immunostaining of the incidental ICC hyperplasia in the colon (×20); 
(insert) immunopositive for CCK2R hyperplastic ICC and ganglion cells of Auerbach’s plexus (×400). (G, H) 
Immunopositive for CCK2R micro-GISTs (×100). 
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In vivo effect of CCK2R activation by gastrin on tumour growth, cell proliferation and 
KIT signalling  
To assess the effects of CCK2R activation in vivo, mice carrying GIST xenografts were 
stimulated with gastrin for 10 weeks. Remarkably, a two-fold volume increase of tumours 
exposed to gastrin in comparison with non-stimulated controls (p = 0.03) was observed (Figure 
4A, B). In addition, the proliferative activity was significantly increased under gastrin 
stimulation, as evidenced by higher mitotic count and Ki-67 labelling index in tumours from 
gastrin-exposed versus control mice (p = 0.04 and p = 0.008, respectively) (Figure 4C, D). 
 
Figure 4. Effect of gastrin exposure on GIST xenografts. (A) Tumour volume assessment: two-fold increase in 
the volume of gastrin-stimulated tumours (gastrin) versus controls (p = 0.03). (B) Tumour weight measurement 
showed > 70% increment due to gastrin stimulation. (C) A statistically significant increase of Ki-67 proliferation 
index was observed for gastrin-stimulated tumours (p = 0.04). (D) Mitotic activity was significantly higher in 
gastrin-stimulated versus non-stimulated tumours (p = 0.008). Results are presented as box plots showing 
maximum, minimum, interquartile range and median. 
By WB, gastrin stimulation resulted in increased phosphorylation of KIT kinase (p-KITY703 
and p- KITY719 increased by 1.4- and 1.3-fold, respectively), and in a remarkable increase of 
PKC-θ kinase activation (22-fold), resulting in evident AKT (2.5-fold), MAPK (8.0-fold) and 
S6 (1.3-fold) hyperactivation. The apoptotic index was not affected (Figure 5). 
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Figure 5. Western blot and densitometry analysis. (A) Immunoblots showing the effect of gastrin stimulation on 
KIT–PKC-θ signalling in GIST xenografts. Actin served as the loading control. (B) Results of densitometry are 
presented according to the formula: (average densitometry assessment gastrin-stimulated tumours/average 
densitometry assessment control tumours) - 1. 
Discussion 
In this study, characterization of CCK2R in GISTs was performed in search for potential 
clinicopathological correlations. Analysis at the genomic level revealed mono-allelic loss of 
CCK2R in 13.7% of cases, but this loss did not have impact on receptor expression. No somatic 
CCK2R mutations were found. The potential role of CCK2Ri4sv in GIST pathogenesis was 
suggested by Korner and co-workers [32], who found CCK2Ri4sv transcripts in all (n = 4) 
examined samples. In our study, the presence of the CCK2Ri4sv in GISTs was confirmed, albeit 
with lower frequency (six of 20 GISTs analysed). CCK2Ri4sv has previously been shown to 
stimulate cell proliferation in vitro and in vivo [33, 35]. Nevertheless, we found CCK2Ri4sv to 
be present only in low/intermediate risk tumours, with four of six positive cases presenting a 
low (≤ 5/50 HPFs) mitotic index. Thus, CCK2Ri4sv seems to have a marginal role in GIST 
progression, similarly to what is observed in other tumour types.  
We confirmed by qRT–PCR that CCK2R is frequently expressed in GIST, as previously 
indicated [14–16]. Notably, the incidence and level of CCK2R mRNA expression were highly 
correlated with gastric site of tumour origin. Moreover, the level of expression was higher in 
tumours of low malignancy potential in comparison with high-risk/malignant ones, suggesting 
a possible role of CCK2R in early stages of GIST development. These associations were 
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confirmed by an in silico analysis of a previously published gene expression dataset of a cohort 
of 62 primary GISTs [13]. Our results were corroborated at the protein level by IHC performed 
on GIST-TMA. The difference in frequency of CCK2R expression between tumours of gastric 
and non-gastric origin was highly statistically significant (p < 0.0001). This clearly illustrates 
that CCK2R expression depends predominantly on the tumour primary site.  
Importantly, we found that CCK2R was also expressed in incidental ICC hyperplasia and 
gastric micro-GIST. Microscopic foci of sporadic KIT-positive spindle cell ICC hyperplasia 
and better delineated micro-GISTs (tumours < 1 cm; designated also as ‘GIST tumourlets’ or 
‘seedling GISTs’) have been introduced as terminology for small preclinical lesions that most 
likely need additional stimuli to evolve into clinically relevant GISTs [7]. Incidental micro-
GISTs are common in gastro-oesophageal resections (2.9– 35%), contrasting with their 
intestinal counterparts (≤ 0.1%) [7–11]. In a recent study of 170 GISTs of small size, the vast 
majority (77%) of micro-GISTs were located in the stomach [42]. The remarkable variation in 
the incidence of micro-GISTs at different GI tract sites suggests an origin from heterogeneous 
subsets of ICC, with varying potentials for neoplastic transformation. Alternatively, other 
factors might contribute to GISTs growth and progression, such as gastric site-dependent 
growth factors and/or mitogens released by the gastric mucosa cells or other components of 
motility-related mechanisms in the stomach microenvironment. Given the common expression 
of CCK2R in preclinical lesions (ICC hyperplasia and micro-GIST) and clinical GISTs from 
the stomach, it is tempting to suggest a possible role of gastrin and CCK2R in the early stages 
of GIST evolution, and particularly in tumours of gastric origin. In humans, clinical data from 
hypergastrinaemic patients (such as those with gastrinoma or chronic proton pump usage) 
clearly demonstrate that hypergastrinaemia alone does not increase the risk of gastric 
carcinoma [22, 43, 44]. Conversely, gastrin is up-regulated locally in 78% of premalignant 
adenomatous colon polyps, before the appearance of invasive carcinoma [44], and gastrin 
expression has been linked to key mutations in the initiation of colorectal carcinogenesis. 
Autocrine gastrin may also have a role in the development of colorectal tumours, as expression 
occurs early in the adenoma–carcinoma sequence [22]. Our data indicate that GISTs do not 
produce their own gastrin. However, its local production by G cells in the deep crypts of the 
stomach mucosa might give rise to the gastrin levels across the whole gastric wall. In this 
context, it would be interesting to investigate whether systemic hypergastrinaemia leads to 
increased GIST incidence in a well-designed epidemiological study. 
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The novel findings coming from our in vivo experiments support the important role of gastrin 
and CCK2R in GIST pathogenesis. GIST xenografts stimulated by gastrin presented significant 
increase of tumour volume and tumour cell proliferation rates in comparison with the non-
stimulated control. Moreover, remarkable increase in PKC-θ and KIT phosphorylation with the 
subsequent over-activation of major downstream KIT signalling pathways (AKT and MAPK) 
was observed. These data confirm the role of CCK2R in GIST pathogenesis, possibly through 
PKC-θ activation.  
In summary, we have shown the expression of CCK2R in incidental ICC hyperplasia and early 
stages of gastric GIST development, associated with predominant CCK2R presence in tumours 
of gastric origin. In vivo study demonstrated the promoting role of gastrin stimulation on GIST 
growth. Whether the inhibition of CCK2R can play a role in the management of patients with 
GISTs warrants further studies. 
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Supplementary methods 
End-point PCR protocol 
PCR was carried out on 2 µl cDNA or first-round PCR product with 2.5 U Taq Polymerase 
(Roche), 0.2 mM dNTPs (Roche) and 0.2 µM of both sense and antisense primers in a 50 µl 
reaction volume. The first-round reaction was cycled 35 times for 30 s at 95°C, 30 s at 58°C 
and 2 min at 72°C. The second-round reaction included 37 cycles of 30 s at 95°C, 30 s at 58°C 
for the wild-type receptor or 56°C for the splice variant, and 30 s at 72°C. Reactions were run 
at least in duplicate. As negative control, no template was added. Furthermore, B-actin control 
PCR reactions were run for each sample with 32 cycles comprising 30 s at 94°C, 45 s at 59°C 
and 1 min at 72°C. PCR products of both first and second round were purified with QIAquick 
PCR Purification Kit (Qiagen). Finally, 10 µl final PCR products were resolved on a 1.5% 
agarose/TAE gel, along with a 1 kb Plus DNA Ladder (Invitrogen) as molecular weight marker, 
and visualized by SYBR® Safe DNA Gel Stain. Representative bands were excised and DNA 
isolated with Zymoclean Gel DNA Recovery Kit (Zymo Research). 
GIST-TMA construction  
For TMA construction, the paraffin GIST blocks were retrieved from the files of the 
Department of Pathology, University Hospitals Leuven and Department of Pathology, 
Bergonie Institute, Bordeaux. At least three cores from each tumour were sampled in order to 
handle intra-tumoral heterogeneity. Every TMA contained cores from colon carcinoma, 
rhabdomyosarcoma, dedifferentiated liposarcoma, melanoma, synovial sarcoma and liver 
reference tissue, as an internal control for IHC. Normal stomach specimens were also included 
in the study. 
CCK2R/gastrin IHC protocol 
After rehydration through UltraClear (JTB Baker) and ethanol, TMA slides were incubated in 
methanol containing 0.003% H2O2 v/v for 20 min, washed twice in 1x PBS–Tween [0.01 M 
PBS/0.5% Tween 20 (Merck), pH 7.4], followed by five washes in H2O. To achieve epitope 
unmasking, slides were heated at 95ºC in TRIS–EDTA buffer [10 mM Tris (Sigma-Aldrich) 
and 1 mM EDTA (Merck), pH 9.0] for 30 min. Next, the slides were cooled for 20 min, then 
rinsed three times for 3 min in PBS–Tween. After incubation with Protein Block Serum Free 
(Dako) for 10 min, the overnight (at 4°C, humid chamber) incubation with primary goat anti-
CCKBR (dilution 1:300; EB06767, Everest Biotech) or rabbit anti-gastrin (dilution 1:200; 
Thermo Scientific) antibodies, diluted in antibody diluent (Dako), was performed, followed by 
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three 5 min washes with PBS–Tween. Next, the slides were incubated with secondary anti-goat 
streptavidin–HRP (GHP516, Goat HPR-Polymer Kit, Biocare Medical) or anti-rabbit 
streptavidin–HRP [Envision+ System, HRP-labelled polymer (Dako)] for 10 min in a humid 
chamber. After consecutive washes with PBS–Tween (three times for 5 min) peroxidase 
activity was revealed (for 5–10 min) with DAB substrate (Dako). The pattern of subcellular 
distribution of CCK2R was recorded as cytoplasmic (without distinct nuclear staining) or 
mixed (nuclear and cytoplasmic). Positive, negative and internal tissue controls were included 
in the study and the results are shown in Figure 3. 
Validation of anti-CCK2R antibody by absorption experiment 
In the absorption experiment, the primary goat anti-CCKBR (EB06767; Everest Biotech) was 
first pre-incubated with the Immunizing Peptide (EBP06767; Everest Biotech). Dilutions were 
made in antibody diluent (Dako) to obtain an antibody:peptide ratio of 1:20 mol; deionized 
water was used instead of peptide solution in a parallel control study. Pre-incubation was 
performed at 4°C overnight, with rotation. Samples were processed as described in the IHC 
protocol and the pre-absorbed or control antibody solutions were used as primary antibody. 
The results are shown in Supplementary Figure S1. 
Validation of anti-gastrin antibody 
To show that the labelling was specific, the primary rabbit anti-gastrin (dilution 1:200; Thermo 
Scientific) antibody was replaced with negative control rabbit immunoglobulin fraction (X 
0903, Dako). Dilutions were made in antibody diluent (Dako) at the same protein concentration 
as the primary antibody. The IHC protocol was performed as described above. The results are 
presented in Supplementary Figure S2. 
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Table S1. List of primers 
 
 
 
  
Target Sequence (5’ → 3’) 
Amplicons for CCK2R mutation analysis 
CCK2R exon 1 
F: CAGCGTGAGCAGGTGGAG 
R: ACCCCCATGAGGTAGGAAAC 
CCK2R exon 2 
F: GCCTGAGGACTGTCACCAAT 
R: GCGAGAGATAAGCCCGTAGG 
CCK2R exon 3 
F: GCCTCGTGTGCTGCAGTG 
R: TGAATGAAGGAGATAGGAGCAC 
CCK2R exon 4 
F: CCAAGCTGCTGGCTAAGAAG 
R: CCTCCTTTCCCATGTACTGCT 
CCK2R exon 5 
F: GGCCTACGGGCTTATCTCTC 
R: AGTTGCACGTAGCAGCCATC 
  
Amplicons for quantitative RT–PCR 
CCK2R 
F: CGCCAGACCTGGTCCGTACT 
R: GCCCGCCTTGGTTTCG 
CCK2Ri4sv 
F: CGCCAGACCTGGTCCGTACT 
R: CCCGTCGCCCTCCAAA 
GUSB 
F: AGGTGGTGCTGAGGATTGG 
R: CCCTCATGCTCTAGCGTGTC 
HPRT 
F: TGACACTGGCAAAACAATGCA 
R: GGTCCTTTTCACCAGCAAGCT 
  
Amplicons for nested PCR 
CCK2R_TOT 
F: AAGGCGGTTTCCTACCTCAT 
R: TGCCAGGCTCCATAGTCTCT 
CCK2R_WT 
F: CGCGTGATTGTAGCCACGTG 
R: TTCTGGTGAACAGCCCCTGG 
CCK2Ri4sv 
F: CTCGCGTGATTGTAGCCAC 
R: CTTCCTTCTCACCCTCACC 
B-actin 
F: CCAGCTCACCATGGATGATGATATCG 
R: GGAGTTGAAGGTAGTTTCGTGGATGC 
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Table S2. Clinicopathological characteristics of patients and tumours used for GIST-TMA analysis 
 
CCK2R 
immunopositive# 
(%) 
Statistical analysis  
 
 
p 
 
 
Total (n = 292) 58.2   
Gender     
 Male (n = 176) 57.4 Male vs. female p = 0.7* 
 Female (n = 116) 59.5   
Primary tumour site    
 Gastric (n = 166) 77.7 
Gastric vs. non-gastric 
p < 
0.0001* 
 Intestinal (n = 108) 30.5   
 Other (n = 18) 44.4   
Risk category    
 Malignant/high-risk (n = 145) 41.4 
Malignant/high vs. inter/low  
p < 
0.0001* 
 
Intermediate/low-risk (n = 
147) 
74.8 
  
Mutation status    
 KIT total (n = 200) 51 KIT exon 9 vs. KIT exon 11 p = 0.01** 
 KIT exon 9 (n = 21) 23.8   
 KIT exon 11 (n = 173) 54.3   
 KIT exon 13 (n = 3) 100   
 KIT exon 17 (n = 3) 0   
 PDGFRA total (n = 48) 81.2 KIT vs. PDGFRA  
p = 
0.0001** 
 WT (n = 35) 65.7 KIT vs. PDGFRA vs. WT 
p = 
0.0004* 
 NA (n = 9) 66.6   
#As established by CCK2R immunohistochemistry. 
*2 test. 
**Fisher test, two-tailed. 
NA, not available. 
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Figure S1. Validation of anti-CCK2R antibody by absorption experiment. Representative example of CCK2R 
IHC on normal stomach mucosa and coincidental sub-mucosal micro-GIST. A) Immunopositive for CCK2R 
micro-GIST and parietal/ECL cells of stomach mucosa (which served as internal positive control). (x40). Insert: 
higher magnification of CCK2R positive micro-GIST (x200). B) Positive control: higher magnification of CCK2R 
immunopositive parietal cells within epithelial gastric crypts and negative adjacent sub-mucosal tissue (x400). C) 
Negative control: primary antibody was pre-absorbed with the peptide that had been used for antibody production, 
resulting in negative staining. (x40). Insert: micro-GST (x200). D. Higher magnification of gastric mucosa and 
sub-mucosal tissue from C (x200). 
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Figure S2. Validation of anti-gastrin antibody. Representative example of gastrin IHC on normal stomach mucosa 
and coincidental sub-mucosal micro-GIST. A) Immunonegative for gastrin micro-GIST and immunopositive G 
cells of deep mucosal crypts (which served as internal positive control), with negative adjacent sub-mucosal tissue 
(x40). B) Positive control: higher magnification of gastrin immunopositive G cells within epithelial gastric crypts 
(x400). C) Negative control: rabbit Ig fraction was used instead of primary antibody against gastrin, resulting in 
the total absence of staining (x40). D. Higher magnification of gastric mucosa from C (x200). 
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Abstract 
Insufficiency of phosphatase and tensin homolog (PTEN) occurs in numerous tumor types and 
has been implicated as a resistance mechanism to receptor tyrosine kinase-targeted therapies 
in human cancer. In this study, we have performed a comprehensive molecular and 
immunohistochemical characterization of PTEN in 58 imatinib-naïve and 54 imatinib-treated 
gastrointestinal stromal tumors (GISTs). The findings were correlated with clinicopathological 
data. At the genomic level, PTEN was affected mainly by mono-allelic loss, which was 
significantly less frequent in imatinib-naïve vs imatinib-resistant tumors (9% vs 39%, 
P<0.001). Neither PTEN mutations nor PTEN promoter hyper-methylation were found. By 
immunohistochemistry, PTEN depletion was clearly related to GIST progression. Low PTEN 
protein expression was common (50%) and often paralleled with total immunonegativity in 
imatinib-resistant tumors. The abnormal PTEN protein expression correlated with PTEN loss 
at the genomic level (P=0.001). In addition, the effect of small interfering RNA (siRNA) PTEN 
knockdown on KIT signaling was examined in GIST-T1 and GIST430 cell lines, in the absence 
or presence of a dual PI3K/mTOR inhibitor NVP-BEZ235, alone or in combination with 
imatinib. In both cell lines, siRNA silencing of PTEN resulted in the substantial upregulation 
of PI3K-AKT and MAPK pathways. The MAPK hyperactivation was further potentiated by 
NVP-BEZ235 in the imatinib-sensitive GIST-T1 cells; yet, this effect was counteracted 
efficiently by combined treatment. In the imatinib-resistant GIST430 cells, neither NVP-
BEZ235 alone or in combination with imatinib yielded sufficient inhibition of hyper-
phosphorylated MAPK and downstream intermediate S6 protein. In conclusion, depleted 
PTEN expression associated with mono-allelic PTEN loss occurs frequently in imatinib-
resistant GIST and might serve as a biomarker for stratifying patients for optimal treatment. In 
vitro, the PTEN insufficiency leads to hyperactivation of AKT and MAPK pathways in tumor 
cells. Novel therapies targeting multiple components of the integrated KIT receptor signaling 
pathways in imatinib-resistant GIST warrant further studies. 
 
Keywords: gastrointestinal stromal tumor; imatinib mesylate; PTEN; resistance 
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Introduction 
The phosphatase and tensin homolog (PTEN) is a phosphatase able to convert membrane-
associated phosphatidylinositol 3,4,5-triphosphate back to phosphatidylinositol 4,5-
bisphosphate; thereby it negatively regulates the signaling transduction of the PI3K/AKT 
pathway [1]. After TP53, PTEN represents the second most frequently mutated 
tumorsuppressor gene in cancer. PTEN inactivation has a role in several human neoplasms, 
including glioblastoma, endometrial, prostate, colon, and breast carcinoma. In some of these 
tumors it has been demonstrated that PTEN deficiency is associated with advanced tumor stage 
and therapeutic resistance, especially to targeted therapies of receptor tyrosine kinases and their 
pathways [2]. In breast cancer, PTEN loss confers resistance to the anti- HER2 antibody 
trastuzumab [3]. Similarly, it promotes resistance to EGFR tyrosine kinase inhibitors in 
glioblastoma, colon, and lung cancer [4–6].  
In gastrointestinal stromal tumors (GISTs), KIT and PDGFRA are fundamental therapeutic 
targets; however, the majority of GIST patients eventually develop resistance to imatinib 
mesylate and to other receptor tyrosine kinase inhibitors currently applied in the clinic [7]. This 
resistance is mainly due to the re-activation of KIT signaling by the acquisition of secondary 
KIT mutations. The PI3K/AKT/mTOR signaling pathway represents a crucial driving force for 
the growth, survival, and progression of GIST [8]. In human malignancies, PTEN inactivation 
or insufficiency constitutively activates this pathway [9]. Thereby, GIST patients with PTEN 
deficiency could benefit from alternative therapies targeting the PI3K/AKT/mTOR pathway. 
In line with this concept, an oral mTOR inhibitor everolimus (RAD001, Novartis 
Pharmaceuticals) has been tested in combination with imatinib in phase I-II clinical trials for 
patients with imatinib-resistant GIST, pointing to a potential therapeutic benefit of the 
combined administration [10]. Recent preclinical in vivo studies performed on GIST 
xenografts, using PI3K inhibitors in combination with imatinib, indicated synergistic and long-
lasting effects, and suggested that PTEN inactivation could have an impact on the response to 
this therapy [11, 12]. Yet, currently no studies have been performed to investigate the range of 
PTEN abnormities in imatinib-resistant GIST patients. 
In this study, we have performed a comprehensive molecular and immuno-histochemical 
characterization of PTEN in a heterogeneous cohort of GIST, to assess the incidence and the 
nature of PTEN malfunction during GIST progression and during the course of imatinib 
therapy. Furthermore, we have investigated the impact of small interfering RNA (siRNA) 
PTEN knockdown on KIT signalling in imatinib-sensitive and imatinib-resistant GIST cell 
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lines treated with a dual PI3K/mTOR inhibitor alone or in combination with imatinib, in order 
to better understand the functional consequences of PTEN insufficiency in GIST cells.  
Materials and methods 
Patients and samples 
Pathologic GIST specimens, from patients who underwent a biopsy or surgical resection of 
their tumor at the University Hospitals of Leuven, Belgium, and at the Department of Soft 
Tissue/ Bone Sarcoma and Melanoma M. Sklodowska-Curie Memorial Cancer Center and 
Institute of Oncology, Warsaw, Poland, were retrieved from the Departments of Pathology of 
both institutions. Patients with advanced GIST were treated with imatinib in a dose 400–800mg 
per day. The majority of these patients acquired resistance to imatinib, which was clinically 
defined as progressive tumor growth that occurred after an initial period 46 months on imatinib 
during which the patient had responsive disease. Both response and progression have been 
objectively assessed according to RECIST criteria. Clinical information was obtained from the 
databases and from review of medical charts. The local institutional ethics board of both 
participating institutions approved the study.  
In total, 112 specimens from imatinib-naïve (n=58, 49 primary and 7 metastatic) and imatinib-
treated (n=54; 48 imatinib-progressive and 6 imatinib-responsive) GIST were available for the 
analysis (Table 1).  
The pathologic material was examined and the diagnosis of GIST was confirmed using 
hematoxylin and eosin staining and CD117 (KIT) immunohistochemistry on formalin-fixed, 
paraffin-embedded tissues, according to standard procedures. KIT/ PDGFRA genotyping was 
done as reported [13].  
PTEN Copy Number Loss, Mutational Analysis, and Methylation Status  
Dual-color interphase fluorescence in situ hybridization (FISH) was performed on 85 paraffin-
embedded specimens, using LSI PTEN(10q23)/ CEP10 Probe (Abbott Laboratories, Green 
Oaks, IL, USA), as described [12]. The array comparative genomic hybridization (aCGH) data 
from 54 GIST included in this study were published before by our group [14, 15].  
Mutational analysis of the entire coding sequence of PTEN (ENST00000371953-exons 1–9) 
was performed as described [12]. The primer sequences are listed in Table 2.  
The methylation status of the PTEN promoter (CpG Island 101755) was evaluated using the 
EpiTect Methyl qPCR Assay (Qiagen) according to the manufacturer’s protocol. Universal 
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Methylated Human DNA Standard (Zymo Research, Freiburg, Germany) and Human Genomic 
DNA (Roche, Basel, Switzerland) were used as positive and negative controls, respectively.  
PTEN Expression Analysis  
For the reverse-transcriptase quantitative PCR (RT-qPCR), total RNA (1 mg) was reverse 
transcribed with SuperScript III (Life Technologies, Carlsbad, CA, USA). The cDNA product 
was amplified using qPCR MasterMixPlus for SYBR®Green I without UNG (Eurogentec, 
Seraing, Belgium) in a Light Cycler 480 (Roche). The endogenous reference GADPH gene and 
the normal stomach tissues were used as references to normalize the results. PTEN expression 
was considered abnormal if the ΔΔCt PTEN/GADPH value was <0.6.  
The PTEN protein expression was assessed by immunohistochemistry in 112 GIST using anti- 
PTEN antibody (DAKO, Glostrup, Denmark; dilution 1:1000) previously validated on GIST 
xenografts with a known PTEN status [12]. Scoring for PTEN staining was semi-quantitative, 
based on the proportion and intensity of positive neoplastic cells (Figure 1). It was performed 
in parallel by two observers using a four-tier system, ranging from 3+ (>50% immune-reactive 
cells and strong intensity equal to that of the vascular endothelium; Figures 1a and b), 2+ (>50% 
immune-reactive cells and weak intensity of staining; Figures 1c and d), 1+ (<50% immune-
reactive cells, referred to as reduced staining; Figure 1e) to 0 (completely negative; Figure 1f). 
The categories 0 and 1+ were considered to be abnormal.  
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Figure 1. Examples of the PTEN immunostaining in GIST. Normal staining was defined as intense, cytoplasmic, 
and nuclear PTEN immunoreactivity in majority of tumor cells, with the staining intensity equal to that of the 
vascular endothelium (which served as internal positive control); original magnifications x100 (a) and x400 (b). 
The weaker reactivity of neoplastic cells in comparison with the vascular endothelium in >50% of the neoplastic 
cells; original magnification x200 (c) and x100 (d). Reduced (e) or absent (f) PTEN expression in tumor 
specimens; original magnification x200. Immunostains counterstained with hematoxylin. 
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In vitro siRNA PTEN Experiments 
In vitro studies were performed on imatinib-sensitive GIST-T1 (carrier of KIT-V560_Y579del 
mutation) and imatinib-resistant GIST430 (carrier of primary KIT-V560_L576del and 
secondary KIT-V654A mutations) cell lines.  
The compounds, imatinib mesylate and the dual PI3K/mTOR inhibitor NVP-BEZ235, were 
purchased from Sequoia Research Products (Pangbourne, UK).  
The siRNA experiments were performed by the use of predesigned stealth RNAi duplexes 
against human PTEN (PTEN Validated Stealth RNAi: PTENHSS183790 + PTENHSS183791 
+ PTENHSS183792; Invitrogen). Transient transfection was done in six-well plates at a density 
of 106 cells/plate with use of metafectene transfection reagent (Biontex, Planegg, Germany), 
according to the manufacturer’s instructions. After 96 h, medium was exchanged for the one 
supplemented with dimethyl sulfoxide (Sigma-Aldrich, St Louis, MO, USA) only, or 100nM 
NVP-BEZ235, or 200nM imatinib, or the combination of both drugs in a given concentration. 
After 2 h of treatment, the cell pellets were collected for protein analysis by western blotting. 
The antibodies against total KIT and total PTEN (DAKO), total MAPK (Invitrogen), phospho-
KIT, phospho-AKT, total AKT, phospho- MAPK, phospho-S6, total S6 (Cell Signaling, 
Beverly, MA), and B-actin (Sigma-Aldrich) were applied. 
Statistics 
For statistical analysis of the qPCR data, the Mann–Whitney U-test was applied. For analyses 
of the frequency of the genomic PTEN losses and the abnormal PTEN expression by 
immunohistochemistry, the χ2 or Fisher exact tests were applied.  
Differences with P-value <0.05 were defined as statistically significant. The software 
STATISTICA (Stat Soft, USA—version 9.0) was used for statistical calculations. 
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Table 1. Clinical, histopathologic and molecular findings of 112 GIST under study.      
               
No. 
Age 
[years] 
Gender 
Primary Tumour Type of 
tissue at 
the time 
of 
surgery 
Primary genotype 
Secondary 
mutation 
PTEN loss PTEN expression 
PTEN 
methylation 
PTEN 
mutation Primary 
site 
Size 
[mm] 
MI 
[per 
50 
HPF] 
aCGH FISH 
RT-
PCR 
IHC 
1 65 M Colon 25 35 IM-PD KIT 11 p.D579del 
not 
detected 
nd yes 0.1 0 negative nd 
2 59 F Stomach 100 52 IM-PD 
KIT 11 
p.Q556_V559delinsH 
KIT 13 
p.V654A 
nd yes 0.38 0 negative negative 
3 54 F Intraabd  NA NA  IM-PD WT KIT ampl nd yes nd 0 negative nd 
4 42 M Stomach 100 NA IM-PD 
KIT 11 
p.W557_K558del 
KIT 14 
p.T670I 
nd yes nd 0 negative negative 
5 47 F Sm Int 10 7 IM-PD KIT 11 p.V559D 
KIT: 
p.D820G 
nd yes 0.55 0 negative negative 
6 49 M Stomach 65 120 IM-PD 
KIT 11 p. 
K558_G565delinsR 
not 
detected 
nd 
yes 
(homo) 
0.04 0 nd nd 
7 51 M Sm Int 12 >10 IM-PD KIT 11 p.K550_K558del 
KIT 17 
p.D820Y 
nd yes 0.1 0 negative nd 
8 70 M Stomach NA NA IM-PD 
KIT 11 
p.W557_K558del homo 
KIT 14 
p.T670I 
nd no nd 0 negative nd 
9 39 M Duod NA NA IM-PD 
KIT 11 
p.W557_K558del 
not 
detected 
nd yes nd 0 negative nd 
10 55 M Colon NA NA IM-PD KIT 11 p.V569_L576del 
not 
detected 
nd yes  0.01 0 negative negative 
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11 47 M Sm Int NA 38 IM-PD KIT 9 p.A502_Y503dup 
not 
detected 
nd no 0.95 1 negative negative 
12 59 M Sm Int NA NA IM-PD KIT 11 p.L576P 
KIT 17 
p.D820Y 
nd yes 0.43 1 negative negative 
13 40 M Intraab 240 25 IM-PD KIT 11 p.V559G 
KIT 13 
p.V654A 
yes yes nd 1 negative negative 
14 67 M Sm Int 40 60 IM-PD 
KIT 11 
p.K550_K558delinsQ 
KIT 17 
p.D820Y 
nd no 1.75 1 negative nd 
15 45 M Sm Int 60 28 IM-PD 
KIT 11 p.W557_T574del 
homo 
KIT 17 
p.N822K 
nd yes nd 1 negative negative 
16 57 F Stomach 150 NA IM-PD KIT 11 p.P573_T574dup 
KIT 13 
p.V654A 
nd yes nd 1 negative negative 
17 45 M Sm Int 9 40 IM-PD 
KIT 11 
p.N567_L576delinsI 
not 
detected 
nd no 2.5 1 negative nd 
18 52 F Sm Int NA 25 IM-PD KIT 9 p.A502_Y503dup 
not 
detected 
nd yes 0.54 1 negative negative 
19 
45 M 
Sm Int 35 75 IM-PD 
KIT 11 
p.W557_K558del 
KIT 17 
p.D816G 
no no 1.34 1 negative nd 
20 
Colon 
meta 
13 20 Met 
KIT 11 
p.W557_K558del 
nd no no nd 1 negative nd 
21 59 F Sm Int 8 3 IM-PD KIT 9 p.A502_Y503dup 
not 
detected 
nd yes nd 1 negative nd 
22 33 F Stomach Multiple 46 IM-PD WT 
not 
detected 
nd yes 0.3 1 negative nd 
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23 46 M Sm Int NA NA IM-PD KIT 11 p.K558delinsNP 
not 
detected 
nd yes nd 1 negative nd 
24 64 M Sm Int 40 15 IM-PD KIT 9 p.A502_Y503dup 
not 
detected 
no no nd 1 nd nd 
25 65 M Rectum NA 47 IM-PD 
KIT 11 
p.W557_V559delinsF 
not 
detected 
nd yes 0.31 1 negative negative 
26 38 F Sm Int 90 9 IM-PD 
KIT 11 
p.Q556_E561delinsQ 
not 
detected 
no no 0.97 2 negative nd 
27 49 M Colon 75 15 IM-PD KIT 11 p.M552_E554del 
BRAF 
V600E 
nd no nd 2 negative negative 
28 72 M Rectum NA 4 IM-PD KIT 11 p.K558N 
BRAF 
V600E 
nd no nd 2 nd nd 
29 58 M Colon >10 >10 IM-PD KIT 9 p.A502_Y503dup 
not 
detected 
nd no 1.05 2 nd nd 
30 63 F Sm Int 12 10 IM-PD KIT 9 p.A502_Y503dup 
not 
detected 
nd no 0.93 2 negative nd 
31 56 F Stomach 95 10 IM-PD WT 
not 
detected 
nd no 1.8 2 nd nd 
32 56 M Sm Int 10 14 IM-PD KIT 9 p.A502_Y503dup 
not 
detected 
nd no 1.21 2 negative negative 
33 43 M Stomach 8 15 IM-PD 
KIT 11 
p.W557_K558del hom 
KIT 13 
p.V654A 
nd no 1.56 2 negative nd 
34 55 F Sm Int 70 11 IM-PD KIT 11 p.W557R 
KIT 17 
p.N822K 
no no 1.19 2 negative negative 
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35 51 M Sm Int 15 0 IM-PD 
KIT 11 
p.W557_K558del 
KIT 17 
p.N822K 
nd no 1.25 2 nd nd 
36 76 M Sm Int NA 55 IM-PD KIT 9 p.A502_Y503dup 
not 
detected 
nd no 0.53 3 negative nd 
37 50 F Stomach NA 52 IM-PD WT 
not 
detected 
no no 3.79 3 nd nd 
38 
41 M 
Colon 38 14 IM-PD KIT 9 p.A502_Y503dup 
not 
detected 
no no 1.23 3 nd nd 
39 Colon 80 2 Met KIT 9 p.A502_Y503dup nd no nd 1.23 3 negative negative 
40 44 M Intraab NA 25 IM-PD KIT 9 p.A502_Y503dup 
KIT 13  
p.V654A 
nd no 1.36 3 negative negative 
41 12 F Stomach multiple 25 IM-PD WT 
not 
detected 
no no nd 3 nd nd 
42 22 F Stomach 230 51 IM-PD KIT 11 p.I563_Q575del 
KIT 17 
p.D820Y 
nd no nd 3 nd nd 
43 41 F Sm Int 150 17 IM-PD KIT 9 p.A502_Y503dup 
not 
detected 
nd yes 0.49 3 nd nd 
44 66 F Stomach 50 126 IM-PD PDGFRA 18 p.D842V 
not 
detected 
nd no 3.16 3 nd nd 
45 56 M Sm Int 10 100 IM-PD KIT 11 p.E554_D572del 
KIT 13  
p.V654A 
nd no 1.9 3 nd nd 
46 54 M Sm Int 16 20 IM-PD KIT 9 p.A502_Y503dup 
not 
detected 
nd no 1.63 3 negative negative 
47 56 M Sm Int 2 10 IM-PD KIT 11 p.V560E homo 
not 
detected 
nd no 0.86 3 nd nd 
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48 73 M Sm Int 10 60 IM-PD KIT 11 p.V560D 
KIT 13 
p.V654A 
nd no nd 3 nd nd 
49 37 F Stomach NA NA IM-PD WT 
not 
detected 
nd yes 0.21 3 nd nd 
50 43 F Sm Int 6 15 IM-PD KIT 9 p.A502_Y503dup 
not 
detected 
nd no 1.6 3 negative negative 
51 50 M Sm Int 7 2 
IM-
RESP 
KIT 11 
p.M552_W557del 
not 
detected 
nd no 2.08 1 negative negative 
52 34 F Stomach 6 10 
IM-
RESP 
WT 
not 
detected 
nd no nd 2 negative nd 
53 47 F Sm Int 12 1 
IM-
RESP 
KIT 11 
p.K558_G565delinsR 
not 
detected 
nd nd 2.43 1 nd nd 
54 33 M Sm Int >10 12 
IM-
RESP 
KIT 11 
p.V559_Y568delinsDND 
not 
detected 
nd yes nd 1 negative nd 
55 19 F Stomach 25 10 
IM-
RESP 
PDGFRA ex4 
not 
detected 
nd no nd 2 negative nd 
56 49 F Sm Int NA NA 
IM-
RESP 
KIT 11 
p.W557_K558del 
not 
detected 
nd no 1.75 2 negative negative 
57 74 M Stomach 90 200 Met KIT 11 p.V560D nd yes yes 0.4 1 negative negative 
58 63 F Sm Int NA 21 Met KIT 9 p.A502_Y503dup nd nd no 0.82 1 negative negative 
59 61 F 
Liver, 
primary 
unknown 
NA 55 Met 
PDGFRA 18 
p.R841_M844delinsR 
homo 
nd yes nd nd 2 nd nd 
60 61 M Sm Int 80 5 Met KIT 17 p.N822K nd no no 2.23 2 negative negative 
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61 78 M Sm Int 280 5 Met 
KIT 11 
p.W557_V559delinsF 
nd no no 0.74 1 negative nd 
62 25 F Stomach 170 31 High 
PDGFRA 18 
p.D842_H845del homo 
nd no no nd 1 nd nd 
63 48 F Stomach 70 14 High PDGFRA 18 p.D842V nd no nd nd 1 nd nd 
64 61 M Sm Int 38 7 High KIT 9 p.A502_Y503dup nd no no 1.02 1 nd nd 
65 68 M Sm Int 76 8 High 
KIT 11 
p.M552_E554delinsK 
nd no no nd 1 negative negative 
66 57 M Stomach >10 23 High 
KIT 11 
p.W557_V559delinsF 
nd no no 1.45 1 nd nd 
67 65 M Sm Int 150 17 High KIT 9 p.A502_Y503dup nd no nd nd 2 negative negative 
68 65 F Stomach 180 60 High 
KIT 11 
p.W557_V560delinsF 
nd no no 2.0 3 nd nd 
69 69 M Mesent 120 21 High KIT 11 p.V560D nd nd yes nd 3 negative negative 
70 48 F Stomach 50 37 High KIT 11 p.K550-V555del nd nd no 1.33 3 nd nd 
71 59 M Sm Int 35 7 High 
KIT 11 
p.V560_L576delinsD 
nd no nd nd 3 negative negative 
72 78 M Sm Int 55 12 High KIT 11 p.V560D nd nd no 1.03 3 nd nd 
73 72 M Oesoph 20 11 High 
KIT 11 
p.K558_V559delinsN 
homo 
nd no no 1.0 3 nd nd 
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74 44 F Stomach 160 4 High KIT 11 p.W557R nd yes yes 0.84 3 nd nd 
75 69 M Stomach 40 11 Intermed 
PDGFRA 18 
p.D842_H845del 
nd no nd nd 2 nd nd 
76 83 F Stomach 85 7 Intermed KIT 11 p.V560D nd nd no 1.06 2 nd nd 
77 75 F Stomach 110 1 Intermed PDGFRA 18 p.D842V nd no nd nd 2 nd nd 
78 69 M Stomach >100 4 Intermed KIT 11 p.L576_R588dup nd no nd 0.96 2 nd nd 
79 51 M Stomach 130 2 Intermed PDGFRA 18 p.D842V nd no nd nd 2 nd nd 
80 76 F Stomach 30 17 Intermed PDGFRA 18 p.D842V nd nd nd 0.76 2 negative negative 
81 53 M Duod 55 5 Intermed KIT 11 p.L576P nd no no 1.59 3 nd nd 
82 68 F Duod 30 4 Intermed KIT 11 p.V560A nd no nd 1.39 3 nd nd 
83 67 F Stomach 40 25 Intermed KIT 11 p.W557R nd no no 1.58 3 nd nd 
84 50 F Sm Int 50 5 Intermed KIT 9 p.A502_Y503dup nd no no  4.08 3 nd nd 
85 36 F Stomach 35 60 Intermed 
KIT 11 p.W557-K558del 
homo 
nd no no nd 3 nd nd 
86 47 F Duod 60 2 Intermed 
KIT 11 
p.P577_R588dup; 
p.L589S 
nd no nd nd 3 negative negative 
87 77 F Eosoph 100 5 Intermed KIT 9 p.A502_Y503dup nd nd nd nd 3 nd nd 
88 85 M Stomach 60 5 Low KIT 11 p.V559A nd nd no 1.43 2 nd nd 
89 61 M Stomach 55 5 Low KIT 11 p.V554D nd no no 2.29 2 nd nd 
90 53 M Stomach 60 5 Low KIT 11 p.V559D nd nd 
gain of 
chr. 10 
1.74 2 nd nd 
   Results | PTEN in GIST 
 
- 89 - 
 
91 49 M Stomach 75 4 Low PDGFRA 18 p.D842V nd no no nd 2 negative negative 
92 64 M Stomach 75 6 Low 
KIT 11 
p.W557_K558del 
nd nd nd 0.74 2 nd nd 
93 62 M Stomach 90 5 Low PDGFRA 18 p.D842V nd no nd nd 2 negative negative 
94 72 M Sm Int 48 3 Low KIT 11 p.V560D nd no no 0.83 2 nd nd 
95 46 F Stomach 50 5 Low 
KIT 11 
p.K558_G565delinsN 
nd yes no nd 2 negative negative 
96 80 F Stomach 55 3 Low 
KIT 11  p.581-
590insKWEFPRNRLS 
nd nd no nd 2 negative negative 
97 55 M Stomach 50 5 Low PDGFRA 14 p.N659K nd no nd nd 3 nd nd 
98 68 M Stomach 30 6 Low KIT 11 p.Q556_I563del nd no no 1.55 3 nd nd 
99 44 M Stomach 80 5 Low PDGFRA 18 p.D842V nd no nd nd 3 nd nd 
100 71 M Stomach 55 1 Low 
PDGFRA 18 
p.I843_D846del 
nd no no nd 3 negative negative 
101 83 M Stomach 50 4 Low 
KIT 11 p.573_574dup; 
T574dup; 
Q575_R586dup 
nd no nd 2.51 3 negative nd 
102 73 F Stomach 85 1 Low 
KIT 11 
p.T574_R586insK 
nd no nd nd 3 negative negative 
103 77 F Stomach 60 4 Low PDGFRA 12 p.D561V nd no no nd 3 nd nd 
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104 60 M Stomach 18 2 
Very 
low 
KIT 11 
p.D572_D579dupinsL 
nd no nd 1.2 2 nd nd 
105 82 F Stomach 20 4 
Very 
low 
KIT 11 p.W557R nd no nd nd 2 nd nd 
106 70 F Stomach 25 0 
Very 
low 
KIT 11 p.L576P nd nd no 0.97 3 nd nd 
107 75 M Stomach 30 3 
Very 
low 
PDGFRA 14 p.N659K nd no nd nd 3 nd nd 
108 64 F Stomach 25 2 
Very 
low 
KIT 11 p.W557R nd no nd 2.99 3 nd nd 
109 54 M Stomach 15 0 
Very 
low 
KIT 11 p.P573_H580ins nd no nd 1.8 3 nd nd 
110 66 F Stomach 35 5 
Very 
low 
PDGFRA 18 
p.D842_H845del 
nd no no nd 3 negative negative 
111 73 F Stomach 45 4 
Very 
low 
PDGFRA 18 p.D842V nd no nd nd 3 nd nd 
112 63 F Stomach 25 2 
Very 
low 
PDGFRA 18 p.D842V nd no nd 1.33 3 nd nd 
               
Abbreviations: Sm Int - small intestine; Duod - duodenum; Intraabd - intraabdominal; Oesophag - oesophagus; NA - not available; IM-PD - progressive disease on 
Imatinib; IM-RESP- responsive to Imatinib; Met - metastasis; Intermed - intermediate risk; homo - homozygous; ampl - amplification; nd-not done 
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Table 2. Primers for PTEN mutational analysis and quantitative RT-PCR. 
Target Sequence (5’ → 3’) 
Amplicons for PTEN mutation analysis 
PTEN exon 1 
F:  TTCCATCCTGCAGAAGAAGC 
R:  CTACGGACATTTTCGCATCC 
PTEN exon 2 
F:  AGTATTCTTTTAGTTTGATTGCTGCAT 
R:  CACAAAGTATCTTTTTCTGTGGCTTA 
PTEN exon 3 
F:  GAAAATCTGTCTTTTGGTTTTTCTTG 
R:  TGGACTTCTTGACTTAATCGGTTT 
PTEN exon 4 
F:  TCACATTATAAAGATTCAGGCAATGT 
R:  GTATCTCACTCGATAATCTGGATGACT 
PTEN exon 5 
F:  CCTGTTAAGTTTGTATGCAACATTTCT 
R:  TCCAGGAAGAGGAAAGGAAAA 
PTEN exon 6 
F:  AATGGCTACGACCCAGTTACC 
R:  TCAAATGCTTCAGAAATATAGTCTCCT 
PTEN exon 7 
F:  AATCCATATTTCGTGTATATTGCTGA 
R:  CACCTGCAGATCTAATAGAAAACAAA 
PTEN exon 8 
F:  TGTCATTTCATTTCTTTTTCTTTTCTT 
R:  AAGTCAACAACCCCCACAAA 
PTEN exon 9 
F:  TGTTCATCTGCAAAATGGAATAAA 
R:  CACAATGTCCTATTGCCATTAAAA 
Amplicons for quantitative RT-PCR 
PTEN ex 6/7 
F:  CAA TGT TCA GTG GCG GAA CTT 
R:  TGA ATT GGA GGA ATA TAT CTT CAC CTT 
PTEN ex 6-7/7 
F:  TGG CGG AAC TTG CAA TCC 
R:  TGG GTC CTG AAT TGG AGG AA 
GADPH 
F:  TGACACTGGCAAAACAATGCA 
R:  GGTCCTTTTCACCAGCAAGCT 
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Results 
PTEN Mono-Allelic Loss Occurs in the Progressive Stage of Disease and is Frequent in 
Imatinib-Treated Tumors 
To assess the incidence of PTEN loss at the genomic level, we performed FISH analysis of 85 
samples, and complemented these data with aCGH results available from 54 cases (Table 1). 
In total, loss of PTEN occurred in 26 out of 108 samples (24%); all of those tumors presented 
mono-allelic loss of the PTEN locus except for one, characterized by PTEN nullisomy. 
Concurrent analysis of PTEN status by FISH and aCGH indicated concordance of the results 
in 30 out of 31 cases; only in one specimen, FISH failed to identify a PTEN deletion otherwise 
seen by aCGH.  
Within the imatinib-naïve group, PTEN loss was observed less frequently in very 
low/low/intermediate risk vs high risk/metastatic GIST (P=0.03; Table 3). Of note, the 
incidence of PTEN loss in imatinib-treated tumors was high (39%). As we did not have baseline 
pre-treatment tumor specimens available for comparison, we could not discriminate whether 
PTEN loss added to acquired resistance to imatinib or it was only a reflection of a more 
advanced stage of disease. Nevertheless, there was no correlation between the incidence of 
PTEN loss and the presence of secondary imatinib-resistant KIT mutations in GIST refractory 
to imatinib (P=0.6). Moreover, no significant differences were found between primary high 
risk/metastatic and imatinib-treated GIST (P=0.11). These results argue against the hypothesis 
that PTEN loss would be a direct cause of resistance to imatinib.  
To further elucidate possible mechanisms responsible for aberrant PTEN expression, we 
performed mutational analysis of PTEN in 36 specimens (including 19 imatinib-progressive 
GIST). No somatic mutations were detected. In addition, we assessed PTEN promoter 
methylation in a total of 57 samples (including 24 imatinib-resistant GIST that lacked or 
expressed low level of PTEN protein by immunohistochemistry). None of the examined tumors 
exhibited methylation of PTEN promoter.  
PTEN Mono-Allelic Loss Correlates with Altered PTEN Expression on Transcript and 
Protein Levels  
By RT-qPCR, we investigated the expression of PTEN transcripts in 67 GIST (including 36 
imatinib-resistant tumors). Abnormal PTEN expression was detected in 21% of samples. The 
low level of PTEN transcript expression correlated well with PTEN loss on the genomic level 
(P=0.002).  
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By immunohistochemistry, absent or reduced expression of PTEN protein was observed in 
32% (n=36) of the tumors (Table 3). In the imatinib-naïve cohort, abnormal PTEN protein level 
was detected in high-risk/metastatic but not in low/ intermediate-risk tumors (45% vs 0%; 
P<0.001). In imatinib-treated tumors, abnormal PTEN expression was common (50%); 
notably, all 10 completely PTEN-immuno-negative GIST were from imatinib-progressive 
cohort. The abnormal PTEN protein expression correlated with PTEN loss at the genomic level 
(P=0.001).  
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Table 3. Correlation of PTEN loss by FISH/aCGH and PTEN protein expression by IHC with clinico-pathological data in GIST under study. 
Categories 
PTEN by FISH/aCGH PTEN protein by immunohistochemistry 
n 
with 
loss 
% of 
total 
Statistical analysis 
n absent reduced 
abnormal 
% of total 
Statistical analysis 
  p-value   p-value 
Total 108 26 24     112 10 26 32     
Gender                      
   Male 63 14 22 Male vs. Female p=0.59 64 7 18 39 Male vs. Female p=0.07 
   Female 45 12 27     48 3 8 22     
Primary tumor site                       
   Gastric 52 9 17 Gastric vs. Non-gastric p=0.11 54 4 6 18 Gastric vs. Non-gastric p=0.002 
   Non-gastric 56 17 30     58 6 20 45     
GIST category                       
   Imatinib-naïvea 55 5 9 
Imatinib-naïve vs. Imatinib-
treated 
p< 0.001 58 0 9 16 
Imatinib-naïve vs. Imatinib-
treated 
p<0.001 
         V. low/Low risk 24 1 4 
High risk/Meta vs. Imatinib-
treated 
p=0.11 25 0 0 0.0 High/Meta vs. Imatinib-treated p=0.7 
         Inter. risk 11 0 0 
High risk/Meta vs. Low/Inter. 
risk 
p=0.03 13 0 0 0.0 
High/Meta vs.  
V. low/Low/Inter. risk 
p<0.001 
         High risk 13 2 15 High risk vs. Meta p=0.48 13 0 5 38 High/Inter. vs. Low risk p=0.02 
         Meta 7 2 28    7 0 4 57 High vs. Inter./Low risk p<0.001 
   Imatinib-treated 53 21 40     54 10 17 50     
Mutation status                  WT vs. PDGFRA p=0.2 
   KIT mutants 83 22 26 KIT 9 vs. KIT 11 mutants p=0.2 58 9 23 37.2 KIT 9 vs. KIT 11 p=0.5 
   PDGFRA mutants 18 1 6 KIT vs. PDGFRA mutants p=0.054 19 0 2 10.5 KIT vs. PDGFRA p=0.02 
   KIT/PDGFRA-WT 7 3 43 KIT mutants vs. WT p=0.3 7 1 1 28.5 KIT mutants vs. WT p=0.6 
With secondary KIT 
mutation 
21 9 43 
With secondary KIT mutation 
vs. without 
p=0.6 21 6 6 57.1 
With secondary KIT mutation 
vs. without 
p=0.4 
Abbreviations: aCGH, array comparative genomic hybridization; FISH, fluorescence in situ hybridization; Inter., intermediate; Meta, metastasis; V. low, very low; WT, wild type. 
a Risk of recurrence for primary imatinib naive GIST was assessed according to the Armed Forces Institute of Pathology criteria [23]
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siRNA-Induced Downregulation of PTEN Expression in GIST Cell Lines Results in 
PI3K-AKT-mTOR and MAPK Pathway Activations  
In the PTENsi GIST-T1 and GIST430 cells, the level of PTEN protein was decreased by ~50% 
and 80%, respectively, compared with non-PTENsi cells (Figure 2).  
In imatinib-sensitive GIST-T1, PTEN silencing resulted in overactivation of AKT and MAPK 
(by 1.6- and 1.8- fold, respectively). The AKT hyper-phosphorylation was partially reverted 
by 100nM NVP-BEZ235 in both PTENsi and non-PTENsi cells (by 70% and 85%, 
respectively). As expected, exposure to 200nM imatinib led to complete AKT inactivation in 
non-PTENsi cells, opposite to PTENsi cells, in which still redundant AKT signaling existed, 
as proven by incomplete downstream p-S6 inhibition (six-fold higher in PTENsi vs non-
PTENsi cells). This effect disappeared under the combined treatment regimen. 
Interestingly, NVP-BEZ235 treatment gave rise to MAPK phosphorylation in non-PTENsi 
cells and at higher extent in PTENsi cells (2- and 2.8-fold, respectively). The MAPK activation 
was substantially and equally abolished by imatinib alone or under the combined treatment in 
both, non-PTENsi and PTENsi cells.  
In imatinib-resistant GIST430 cells, knockdown of PTEN induced the increase of p-AKT (3-
fold) and even more remarkable of p-MAPK (24-fold). The AKT phosphorylation was 
significantly inhibited under NVP-BEZ235 or imatinib treatment alone or combination in 
PTENsi and in non-PTENsi cells. In contrast, MAPK hyperactivation in PTENsi cells was still 
substantially higher compared with control cells under both NVP-BEZ235 (5.6-fold) and 
imatinib (6.4-fold). Noteworthy, combined treatment of NVP-BEZ235 with imatinib led still 
to a 4- and 12- fold overactivation of MAPK in non-PTENsi and PTENsi cells, respectively. 
The S6 protein, downstream intermediate of the mTOR pathway, was overactivated by 30% in 
PTENsi cells in comparison with control. The NVP-BEZ235 treatment resulted in reduction of 
S6 phosphorylation in non-PTENsi and, to a lesser extent, in PTENsi cells (80 and 50%, 
respectively). Imatinib treatment induced 40% reduction of p-S6 in control cells; in contrast, a 
60% increase in the level of p-S6 was observed in PTENsi cells. Markedly, this overactivation 
of S6 protein in PTENsi vs non-PTENsi cells was only partially reverted by combined 
treatment.  
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Figure 2. Short interfering (siRNA) knockdown of PTEN in imatinib-sensitive GIST-T1 (a) and imatinib-resistant 
GIST430 (b) cell lines. The effect of PTEN silencing on KIT downstream signaling was evaluated by western 
blotting under DMSO, imatinib, or NVP-BEZ235 alone, or combined treatment. For densitometry analysis, bands 
were normalized to actin expression and compared with control (diluting medium) as previously described [12] 
Discussion 
First, we carried out FISH and/or aCGH analysis of PTEN in a heterogeneous cohort of GIST. 
Monoallelic PTEN loss occurred in 24% of cases, whereas bi-allelic PTEN loss was 
encountered only in one tumor. In the imatinib-naïve GIST, a positive correlation between 
mono-allelic loss of PTEN and high-risk/metastatic tumors were found (P=0.03). These 
findings are in agreement with aCGH analysis reported by Ylipää et al. [17] as they observed 
the loss of chromosome 10q (on which PTEN maps) in the specific GIST subgroup, in patients 
with poor clinical outcome. As such, this event is likely to occur in the late stage of GIST 
evolution. As revealed by RT-qPCR analysis, PTEN loss was associated with substantially 
lower or absent PTEN transcript levels (P=0.002). In contrast to Yang et al. [18] we do not 
have evidence that receptor tyrosine kinase inhibitor treatment can cause loss of PTEN 
expression by epigenetic silencing, as we did not identify PTEN promoter methylation in any 
of the analysed imatinib-resistant GIST. This finding together with the lack of evidence for 
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inactivation of the PTEN by inactivating mutations suggests that the aberrantly low PTEN 
expression in GIST might be mainly due to mono-allelic loss.  
Our findings were corroborated at the protein level by immunohistochemical analysis. In the 
imatinib-naïve cohort, reduced PTEN expression was mainly associated with the high-
risk/metastatic tumors (P<0.001). An inverse correlation between PTEN immunoreactivity and 
disease progression in primary GIST has been previously reported [19, 20]. In our imatinib-
treated GIST, the frequency of tumors with reduced or absent PTEN expression reached 50%. 
This result is notable because to the best of our knowledge data about the incidence of PTEN 
deficiency in imatinib-treated GIST has not been reported as of yet. Importantly, a subset of 
imatinib-progressive GIST with mono-allelic PTEN loss showed complete lack of PTEN 
reactivity by immunohistochemistry, suggesting a bi-allelic inactivation. In these cases, we 
cannot exclude the presence of microdeletions/rearrangements of the second PTEN allele that 
were under the detection limit of the techniques used in the current study. Alternatively, other 
inactivation mechanisms might have a role, as PTEN expression could be positively and 
negatively regulated by transcription factors or microRNAs, as well as posttranslationally 
regulated by phosphorylation, oxidation, and acetylation [1, 2]. Downregulation of PTEN 
results in hyperactivation of the PI3K/AKT/ mTOR pathway, leading to proliferative advantage 
of neoplastic cells. A similar role was attributed to PTEN in other types of cancers [9].  
Subsequently, we explored the effect of siRNA PTEN silencing on KIT downstream signalling 
in vitro using GIST cell lines. Noteworthy, in both imatinib-sensitive and imatinib-resistant 
GIST cells, PTEN silencing resulted in overactivation of both, AKT and MAPK; the latter 
being exceptionally hyper-phosphorylated in imatinib-resistant cells. Overactivation of AKT 
was expected, as PTEN is a negative regulator of the PI3K-AKT pathway, whereas the latter 
might be explained by the extensive mTOR-negative feedback loops and cross-talks between 
the PI3K and the RAS-mediated MAPK pathways that have been well documented among the 
signaling networks driving tumor progression [21, 22].  
Finally, we have investigated the effect of PI3K/ mTOR inhibition, alone or in combination 
with imatinib, on PTENsi GIST cell lines.  
In imatinib-sensitive GIST-T1, NVP-BEZ235 treatment resulted in only partial inactivation of 
AKT in PTENsi cells, whereas enhancing the activation of MAPK. Nevertheless, the effect of 
PTEN silencing on AKT and MAPK activation in these cells was counteracted by imatinib 
alone and even more substantially by the combined treatment of NVPBEZ235 and imatinib.  
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In imatinib-resistant GIST-430 cells, NVP-BEZ235 treatment led to less efficient AKT and 
MAPK inhibition in PTENsi in comparison to non-PTENsi cells. Likewise, imatinib did not 
inhibit sufficiently the overactivated MAPK and downstream S6 proteins in PTENsi cells. 
Combined treatment resulted in still substantial MAPK hyper-phosphorylation, and only 
partially counteracted S6 activation.  
In summary, our data strongly support an important role for PTEN downregulation in GIST 
progression. Partial or total PTEN depletion occurs frequently in imatinib-resistant GIST. In 
vitro studies suggest that PTEN insufficiency leads to upregulation of the PI3K/AKT and 
MAPK pathways. Depending on the molecular context of the individual tumors, the MAPK 
activity might be even paradoxically further enhanced under certain dualspecific PI3K/mTOR 
inhibitors. Our results highlight the importance of molecularly sub-classifying GIST before 
exposing patients to innovative targeted treatments. 
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GENERAL DISCUSSION AND FUTURE PERSPECTIVES 
Tumours development and progression occur as a consequence of alterations in the regulation 
of cell growth and proliferation and of disturbances in the control of the cell cycle and cell 
death (apoptosis). Moreover, disruption of the interactions between cells and their surrounding 
environment favour tumour invasion and metastasis. Two important classes of genes are 
involved in all the aforementioned critical cellular processes, i.e. the proto-oncogenes that 
promote cell division, and the tumour suppressor genes, which repress it. These types of genes 
are the most frequently targeted by genetic changes during malignant transformation. Based on 
observations regarding the development of several human cancers, it is widely believed that 
normal cells need to undergo a multi-step process, characterised by the accumulation of a 
number of genetic aberrations, to eventually become fully malignant. Considering the 
hypothesis that tumours follow a clonal evolution growth, a single cellular progenitor acquire 
the first mutation that enable the cell to reproduce a limited progeny harbouring the same 
genetic alteration. One of these cells subsequently gains a second molecular change, which 
stimulates the growth of a small benign tumour. Then again, one cell from this benign tumour 
mass will acquire a third genetic aberration, proliferate, and form a more advanced tumour. 
Eventually, one cell will accumulate a sufficient number of hits and develop a malignant 
behaviour, undergo uncontrolled proliferation, invade the surrounding tissue and metastasize 
to other organs. Notably, the complexity of the tumour increases when different cells undergo 
“parallel clonal evolutions” and give rise to small subpopulations within the same mass. In this 
case, the tumour is composed of heterogeneous cells which present different potentials for 
growth, differentiation, proliferation and invasion as well as different sensitivities to drugs. 
Tumour heterogeneity represents a critical challenge for the development of successful therapy. 
In addition, the anatomical site of origin and the tumour microenvironment can also influence 
and support the growth of different tumour cells. For instance, in the case of a germ-line 
mutation, where all the cells of an individual harbour the “first hit”, only a particular cell type 
with a permissive molecular context of a specific organ will undergo the tumorigenic process. 
On the other hand, the microenvironment surrounding the tumour can stimulate cancer cells 
proliferation by releasing mitogens and growth factors. All in all, genomic changes, external 
stimuli as well as later therapeutic intervations can influence tumours development, 
composition and progression. The fittest cells, which present selective advantages, will prevail 
in the process of cancer evolution. 
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GIST are neoplasms of the gastrointestinal tract originating from the cells of mixed, myogenic 
and neurogenic phenotype. It is now well accepted that they arise from ICC or from a common 
progenitor. In the majority of cases (85%), the initiating oncogenic event for GIST 
development is a gain-of-function mutation of the tyrosine kinase receptors KIT or PDGFRA, 
which results in ligand independent activation of the receptor and its downstream pathways. 
Most probably, as suggested by Bardsley and colleagues, ICC stem cells carrying a KIT 
oncogenic mutation become hyperplastic and differentiate into ICC mature cells, which give 
rise to ICC hyperplasia [31]. To note, ICC stem cells express only low level of KIT and they 
are not dependent on KIT signalling for survival, opposit to their differentiated progeny. 
Consequently, they are not sensitive to KIT inhibition and will constitute an imatinib-resistant 
reservoir for GIST, increasing the heterogeneity of the tumour mass. A nodular form of ICC 
hyperplasia <1cm in size, caused by somatic acquisition of a KIT mutation is referred to as 
micro-GIST. Strong evidences suggest that micro-GIST are on a biological continuum with 
larger clinical lesions, and most importantly they harbour the same type of KIT/PDGFRA 
mutations [16, 17, 36]. Nevertheless, only a small subset of micro-GIST evolves towards 
clinically relevant tumours, while most of them regress into self-limiting lesions. These 
findings indicate that mutations in KIT/PDGFRA kinase receptors are necessary for GIST 
tumorigenesis but not sufficient for progression to an advanced tumour stage. The biological 
mechanisms required for GIST malignant transformation are still largely unknown. Additional 
genetic hits, epigenetic changes and environmental factors are likely involved in the GIST 
evolution.  
The overarching aim of this thesis was the cytogenetic, molecular and functional 
characterization of GIST. In particular, we investigated the relevance of two selected genes, 
CCK2R and PTEN, which have an impact in opposite time periods of GIST evolution; the 
former being involved at the early phase of tumour growth and the latter in the malignant stage 
of the disease. The understanding of the mechanisms involved in this multi-step hyperplasia-
neoplasia sequence could provide further valuable information on the pathogenesis of GIST 
and could lead to the discovery of new target molecules, both fundamental for the development 
of novel strategies and better tailored, more effective therapies. 
Role of the tumour microenvironment in the early stages of GIST development 
The organ-specific microenvironment surrounding the tumour could affect GIST 
tumorigenesis by releasing factors that support tumour progression. As a matter of fact, the 
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same signalling pathways required for physiological processes and maintenance of 
gastrointestinal homeostasis are also involved in GIST carcinogenesis. 
In this thesis we have shown that gastrin has growth promoting effect on human GIST 
xenografts, as reflected by the larger tumour volume and increased tumour cells proliferation 
rate upon stimulation. Moreover, we observed that CCK2R is frequently expressed in GIST of 
gastric origin and the level of expression was higher in tumours of low malignancy potential in 
comparison with high-risk/malignant ones, irrespective of the KIT/PDGFRA genotype. These 
associations were corroborated by an in silico analysis of a previously published gene 
expression dataset [62]. Notably, we found that CCK2R was also expressed in cases of 
incidental ICC hyperplasia and gastric micro-GIST. In addition, gastrin stimulation led to 
hyper-activation of PKC-θ and KIT kinases, and subsequently over-activation of major 
downstream KIT signalling pathways (AKT and MAPK), as demonstrated in our in vivo 
studies. These findings suggest a promoting role of gastrin and CCK2R in early stages of GIST 
evolution, particularly in tumours from the stomach (which is the prevalevent anatomic site of 
GIST origin). Presumably, once the tumour progresses to more advanced stages by acquisition 
of further genetics changes, the promoting effect of CCK2R expression might eventually 
decrease as other mechanisms will take over to support tumour growth. 
Interestingly, the remarkable over-activation of PKC-θ after gastrin stimulation, 22-fold higher 
comparing to the control xenografts, suggests that CCK2R exerts its function on GIST tumour 
possibly through this kinase. CCK2R activation leads to increased level of DAG, which 
activates PKC-θ by binding the C1 domain of its regulatory subunit. PKC-θ is a 
serine/threonine kinase that is strongly expressed and phosphorylated in GIST [28]. It regulates 
the expression of KIT receptor, and promotes GIST cells survival and proliferation, as 
demonstrated by Wen-bin Ou and colleagues [69]. Intriguingly, GIST originating in the 
intestine are less influenced by the action of gastrin, as they do not usually express CCK2R. 
Moreover, the low occurrence of micro-GIST in this site suggests that intestinal ICC might be 
more prone to acquire distinctive and earlier crucial genetic abnormalities and/or epigenetic 
molecular features associated with selective advantages that promote tumour progression 
toward malignant phenotype. This notion is supported by the well known more aggressive 
biological behavior of intestinal vs gastric GIST. Likewise, there are differences in the 
distribution of GIST molecular subtypes in these anatomic locations; opposit to gastric 
tumours, intestinal GIST harbour frequently KIT exon 9 but very rarely PDGFRA mutations. 
Overall, the anatomical location of primary GIST can effectively influence the type of 
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KIT/PDGFRA mutations, early pathogenetic mechanisms, including stimulation by the 
surrounding microenvironment, the risk of progression and, subsequently, responses to 
treatment.  
Whether the detection and/or inhibition of CCK2R can be useful in the management of patients 
with GIST warrants further studies. The limited expression of CCK2R in normal tissues, 
coupled with the overexpression of CCK2R in various cancers, has rendered the receptor an 
attractive candidate for targeting imaging and therapy. Radioactive conjugates of gastrin or 
nonpeptidic agonists and antagonists of CCK2R have already been explored for use in the 
imaging of CCK2R-overexpressing tumours [233-236], and proved to be the promising agents 
for the localization, sizing, metastasis detection and monitoring of these tumours. Interestingly, 
recently emerging nanotherapy using targeted magnetic nanoparticles grafted with peptic 
ligands of CCK2R to induce cancer cell death could be an effective therapeutic strategy in 
GIST with CCK2R overexpression [237]. However, in the light of our study the use of it would 
be limited mainly to gastric tumours and most likely not applicable in TKi-resistant disease.  
The other interesting issue that comes from our study is the possible influence of 
hypergastrinaemia on promotion of clinically revelant GIST, particularly in the context of 
commonly used PPi. The latter are potent inhibitors of gastric acid secretion and give 
hypergastrinemia secondary to gastric hypoacidity. Hypergastrinemia has been shown to be an 
important factor in the pathogenesis of certain human cancers, including oesophagal and colon 
carcinomas, and gastric carcinoids [234, 236]. Whether long-term PPi treatment can induce 
ICC cell neoplasia and support GIST growth in humans is unknown. Further prospective, well-
designed epidemiological studies or randomized controlled trials related to PPi use and GIST 
risk are needed to investigate the possible association. 
Accumulation of aberrations during malignant GIST progression 
In advanced malignant GIST, a variety of genes related to key biological functions, such as cell 
proliferation (e.g. CDKN2A, RB1, CDK4), apoptosis (e.g. P53, MDM2), invasion and 
migration (e.g. dystrophin), are found frequently mutated, deleted, amplified or silenced by 
promoter hypermethylation. In most of the cases these observations correlated with aggressive 
clinical behaviour and unfavourable prognosis. However, whether these alterations might 
influence the responses to targeted therapy or could represent important biomarkers to improve 
therapeutic strategies is still not very clear. 
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In this thesis we reported that monoallelic loss of PTEN is a frequent event in progressive 
GIST. We observed partial or total loss of PTEN protein expression in advanced malignant 
GIST, especially in tumour that showed resistance to imatinib therapy. Only one patient was 
affected by biallelic PTEN loss, whereas no mutation have been found in the whole gene nor 
the gene has been silenced by promoter methylation in any of the analysed cases. However, the 
expression on PTEN protein can be regulated at different levels and by different mechanisms. 
Additional studies should be performed to investigate the possible other ways of PTEN 
depletion in GIST. Nevertheless, the hypothesis supported by Pandolfi and colleagues that 
PTEN displays the property of ‘obligate haplo-insufficiency’, and even subtle variations of 
PTEN expression could promote cancer progression, cannot be completely excluded. 
PTEN negatively regulates the PI3K/AKT signalling, one of the most crucial pathway in cancer 
progression, and fundamental for GIST tumorigenesis. PTEN inactivation has a role in several 
human neoplasms and it is associated with advanced tumour stage. Moreover, it has been 
demonstrated that PTEN deficiency confers resistance to TKi targeted therapies [154-157]. Our 
results argue against the hypothesis that PTEN loss would be a direct cause of resistance to 
imatinib. Nevertheless, downregulation of PTEN results in hyperactivation of the 
PI3K/AKT/mTOR pathway, which provides proliferative advantages to neoplastic cells. As 
proven in our in vitro studies, silencing PTEN in GIST cell lines resulted in the up-regulation 
of both the PI3K-AKT and the MAPK pathways. Interestingly, NVP-BEZ235, dual 
PI3K/mTOR inhibitor, inactivated AKT; whereas, MAPK hyper-activation was further 
potentiated by this treatment alone. These findings have also been observed in other types of 
cancers [239] and in PTEN-deficient GIST xenografts [223-224]. Most probably, the inhibition 
of the PI3K cascade pushs the tumour to signal through the RAS/MAPK pathway, by releasing 
the mTORC1/S6K/IRS1 feedback loop. Compensatory activation of this alternative growth 
promoting pathway may limit the efficacy of drugs targeting the PI3K signalling cascade. 
Considering the central role of the PI3K pathway in the control of the most important cancer 
cell processes and the increasing evidences of its dysregulation during cancer progression, the 
interest in the development of drugs targeting the PI3K cascade has significantly grown. 
However, the complex network of feedback loops and cross-talks that regulates this pathway, 
emphasise the need of a well-designed treatment strategy. Therapies that combine PI3K 
pathway inhibitors with receptor tyrosine kinase inhibitors have been successfully tested in 
different cancers. In this thesis we have showed that combination treatment of NVPBEZ235 
and imatinib was more efficient than either treatment alone to counteract the effects of PTEN 
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silencing on AKT and MAPK activation in imatinib-sensitive GIST cell lines. However, in 
GIST cell lines that present resistance to imatinib due to the acquisition of a secondary KIT 
mutation, combined treatment surprisingly resulted in still substantial MAPK hyper-
phosphorylation, and only partially counteracted AKT downstream signalling activation. In 
this cell context we suggest that concomitant inhibition of PI3K/AKT and RAS/MAPK 
pathways might represent a successful approach. Additional studies should be conducted to 
confirm the efficacy and to test the toxicity of this drug combination in GIST. 
Our data highlighted the importance of PTEN downregulation in GIST progression. GIST 
patients showing PTEN depletion could benefit from the therapeutic combination of TKi and 
PI3Ki. However, responses to this treatment might depend on KIT mutational status, as residual 
survival signalling and stimulation of a parallel pathway might ensure persistence of a subset 
of GIST cells. From this work, we can further stress the importance to identify predictive 
biomarkers to improve tumour prognostication and risk assessment, and to molecularly sub-
classify GIST to allow the proper selection of patients for appropriate therapies.  
Future directions and perspectives 
Genetic changes in the early stages 
In addition to KIT and PDGFRA mutations, sequential accumulation of other genetic events is 
involved in the progression of GIST to clinically revelant tumours. Since the early stages of 
development, loss of chromosome 14q, and sequentially throughout progression, 22q, 1p and 
15q are the most frequent. The function of crucial tumour suppressor genes might be 
compromise by these changes, conferring selective advantages to the tumour and promoting 
progression from low-risk to overtly malignant GIST. In search of yet unknown genes involved 
in GIST pathogeneis, an integrative analysis of gene profiling and high-resolution genomic 
copy number changes was performed recently by Astolfi and co-workers, providing a more 
comprehensive molecular protrait of GIST and a list of possible tumour suppressor gene 
candidates involved in their progression [240]. However, the significance of their findings is 
still unknown since the putative GIST-related tumour suppressor genes were not supported or 
verified by other studies. 
More efforts are being employed in this direction. During a collaboration in the laboratory of 
Prof. J.A. Fletcher (Department of Pathology, Brigham & Women’s Hospital, Harvard Medical 
School, Boston, MA) we have identified a possible candidate tumour suppressor gene located 
on chromosome 14q which could contribute for GIST progression. Monosomy of 14q is the 
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most frequently observed cytogenetic aberration in GIST, found in 60-70% of cases. It occurs 
at similar frequencies in low-risk and high-risk tumour, suggesting that this aberration 
represents an early event in GIST development. The gene investigated in this study maps in the 
recurrently deleted region of chromosome 14 and it functions as transcriptional repressor. We 
have performed a genomic and molecular characterization of the candidate gene on a 
representative cohort of GIST specimens complemented by functional studies on GIST cells 
lines. The manuscript on this research project is still unpublished and cannot be disclose as yet. 
Genome-wide functional studies  
The discovery of novel target genes involved in GIST development and progression are 
essential also for GIST treatment. During the multi-step process of GIST evolution, 
accumulation of aberrations in tumour suppressor genes and dominant oncogenes leads to 
increased tumour heterogeneity, which can attenuate the response to standard treatment. On 
the other hand, the knowledge of specific genetic hits upon which tumour cells become 
dependent for survival provide sensitive targets for the development of novel therapies.  
Recently, RNA interference (RNAi) screening in combination with the next-generation 
genome sequencing technologies has become an integral tool for elucidation of gene function 
within pathways and signalling networks, and putative target gene discovery [241-244]. Stable 
and persistent gene knockdown has become feasible by integrating shRNAs with lentivirus as 
the delivery system [245].  
Using systematic genome-scale functional genetic technology, in a collaborative effort and 
within the laboratory of Prof. J.A. Fletcher, we sought to discover essential genes and pathways 
involved in GIST pathogenesis and to identify mechanisms of drug response and resistance 
utilizing representative GIST cell lines. 
Genome-wide functional characterization is a powerful and unbiased technique. Two different 
approaches have been developed at the Broad Institute (Genomics centre established by 
Harward Medical School and Massachusetts Institute of Technology). “Loss-of-function” 
genomic screens are genome-scale short-hairpins-RNA (shRNA) screens using pooled 
lentiviral libraries. The use of a pooled shRNA library allows for the systematic correlation of 
gene knockdown with a consequential cell response in a high-throughput manner. The library 
consists of 98K lentiviral shRNA constructs corresponding to 17K genes (~5 non-overlapping 
hairpins per gene) that can be delivered to the cells in a single pooled infection. A 
complementary method to shRNA pooled screens is the high-throughput “gain-of-function” 
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screening technology. This lentiviral expression library comprises 16K distinct Open Reading 
Frames (ORF) mapping to ~14K genes. The ORF pooled library is used to interrogate cell 
responses to altered gene expression. 
In brief, the experimental procedure for the pooled infection is as follows: cells are infected in 
duplicate with a pool of lentiviruses at a ∼0.3 multiplicity of infection and subjected to 
antibiotics selection. Experimental replicates are set up and the cells are then expanded under 
different selective conditions, i.e. untreated or under pharmacologic inhibition of a pathway of 
interest. After ~16 doublings the representation of the initial shRNA/ORF library is assessed 
by deep sequencing on an Illumina platform through the quantification of the relative 
proportion of shRNA/ORF in the surviving cells. Comprehensive statistical and bioinformatic 
analyses of the data are then performed. The analyses comprise an initial QA/QC assessment, 
followed by in-depth custom analyses. To define genes as “hits” based on shRNA/ORF 
depletion/enrichment data a gene score is calculated based on the raw values of the 
hairpin/ORF set. Different methods can be used for gene ranking: best hairpin, second best, 
Kolmogorov-Smirnov-based, or weighted scores. The under- or over-represented shRNA/ORF 
will be considered as playing significant roles in tumour growth/survival mechanisms. Finally, 
Gene Set Enrichment Analysis (GSEA) can be used for pathway analysis. Once the screen is 
completed, follow up on interesting genes/pathways is necessary. Validation of the hits is 
needed to confirm both the specificity of the assay, against off-target effects, and the relevance 
of target genes, understanding the biological mechanisms using different assays and different 
models. 
In the “loss-of-function” approach, depleted shRNA identify essential genes for tumour growth 
and survival (oncogenes), while over-represented hairpins designate genes with tumour 
suppressor-like properties. In the arms subject to pharmacologic selective pressure, synthetic 
lethal interactions can arise when target knock-down synergizes with a specific target 
inhibition. Combined inhibition highlights potential novel treatment strategies. 
In the “gain-of-function” approach, ORF that are expanded most likely represent oncogenes, 
while under-represented ORF define tumour suppressor genes. In the treated arm, the enriched 
ORF represent genes whose expression can rescue the cells from the treatment effects and can 
be responsible for mechanisms of resistance. 
With the collaboration of the Broad Institute, we have performed genome-wide shRNA and 
ORF screens in 4 representative GIST cell lines, paralleled by treatment arms. The analysis 
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revealed potential hits which were followed-up by validation studies and are promising for 
clinical translation. In particular, we investigated the effects of targeted silencing and 
expression of the genes of interest on cell proliferation/growth/survival and relevant pathways 
in all GIST cell lines included in the study. In addition, we tested the efficacy of available drugs 
alone or in combination with TKi that could inhibit the gene of interest or function as synthetic 
lethal. 
An important result obtained from one of these studies, is the identification of CDC37 as 
essential gene in GIST [229]. CDC37 is a kinase-specific HSP90 cochaperone that is required 
for proper folding and function of a number of protein kinases, including KIT and PDGFRA. 
Targeting CDC37 results in down-regulation of KIT expression in both imatinib-sensitive and 
imatinib-resistant GIST cell lines and it might represent a promising strategy to overcome TKi 
resistance due to the presence of heterogeneous KIT/PDGFRA mutations.  
Further analysis are on-going.  
Conclusions 
To date, significant progresses have been made in the understanding of the etiology, diagnosis, 
prognosis and treatment of GIST. The multistep neoplastic process of GIST development and 
progression starts with a gain-of-function mutation of KIT/PDGFRA gene, as initiating 
oncogenic event, subsequent ICC hyperplasia formation, microscopic GIST, low-risk GIST, 
high-risk GIST, metastatic GIST, and eventually TKi-resistant GIST, after TKi treatment. This 
evolution towards malignancy is supported by the stimulation of the surrounding 
microenvironment and by subsequent accumulation of genetic alterations, which enhance 
proliferative capacity of an altered cell and help this cell to escape normal growth control and 
gain selective advantages. Even though there is a common clonal progenitor, different clones 
might diverge with respect to genetic changes and generate tumour heterogeneity. 
In this thesis, we have highlighted the importance of gastrin and CCK2R expression in the early 
stage of GIST development and the important role of PTEN depletion during malignant 
transformation and its influence on targeted therapy. Greater insights into GIST biology, 
heterogeneity and mechanisms of drug resistance, will help to rationally develop more effective 
therapeutic strategies for prolonged disease control and to hopefully eradicate all tumour 
subclones, including possible cancer stem cells, to obtain a true cancer cure. 
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